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Abstract 
 Synthetic biological systems promise to combine the spectacular diversity of 
biological functionality with engineering principles to design new life to address 
many pressing needs. As these engineered systems advance in sophistication, 
there is ever-greater need for customizable, situation-specific expression of 
desired genes. However, existing gene control platforms are generally not 
modular, or do not display performance requirements required for robust 
phenotypic responses to input signals. This work expands the capabilities of 
eukaryotic gene control in two important directions. 
 For development of greater modularity, we extend the use of synthetic self-
cleaving ribozyme switches to detect changes in input protein levels and convey 
that information into programmed gene expression in eukaryotic cells. We 
demonstrate both up- and down-regulation of levels of an output transgene by 
more than 4 fold in response to rising input protein levels, with maximal output 
gene expression approaching the highest levels observed in yeast. In vitro 
experiments demonstrate protein-dependent ribozyme activity modulation. We 
further demonstrate the platform in mammalian cells. Our switch devices do not 
depend on special input protein activity, and can be tailored to respond to any 
input protein to which a suitable RNA aptamer can be developed. This platform 
can potentially be employed to regulate the expression of any transgene or any 
endogenous gene by 3’ UTR replacement, allowing for more complex cell state-
specific reprogramming 
 vi 
We also address an important concern with ribozyme switches, and 
riboswitch performance in general, their dynamic range. While riboswitches 
have generally allowed for versatile and modular regulation, so far their 
dynamic ranges of output gene modulation have been modest, generally at most 
~10-fold. We address this shortcoming by developing a modular genetic 
amplifier for near-digital control over eukaryotic gene expression. We combine 
ribozyme switch-mediated regulation of a synthetic TF with TF-mediated 
regulation of an output gene. The amplifier platform allows for as much as 20-
fold regulation of output gene expression in response to input signal, with 
maximal expression approaching the highest levels observed in yeast, yet being 
tunable to intermediate and lower expression levels. EC50 values are more than 4 
times lower than in previously best-performing, non-amplifier ribozyme 
switches. The system design retains the modular-input architecture of the 
ribozyme switch platform, and the near-digital dynamic ranges of TF-based gene 
control.  
 Together, these developments promise to allow for wider applicability of 
these platforms for better-performing eukaryotic gene regulation, and more 
sophisticated, customizable reprogramming of cellular activity. 
 vii 
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1.1 Synthetic biology expands possibilities  
The work described in this thesis aims to be a very small part in the effort to 
coopt the myriad functionalities that exist in the natural world and to engineer 
new life to address some of our most pressing challenges. After billions of years of 
evolution, we find on our planet an estimated 6 million taxa of prokaryotes, 
encompassing a perhaps unknowable number of genetically distinct organisms 
(Curtis et al., 2002), along with some 8.7 million species of eukaryotes (Mora et al., 
2011). Many of these organisms have multiple cell types, and many have genetic 
programs that can be regulated temporally and spatially. The end result is a 
spectacular diversity of genetically programmed functionality.  
Researchers first directly manipulated genes of living organisms more than 40 
years ago (Jackson et al., 1972), and have since steadily expanded the toolkit of 
genetic engineering technologies. Biochemical understanding and sequencing of 
an ever-increasing number of genomes continues to expand our understanding of 
gene function. And directed evolution, incorporation of non-natural amino acids, 
and high-throughput gene modification and activity screening methods allow for 
development of novel gene function (Bloom et al., 2005; Wang et al., 2009; Isaacs 
et al., 2011; Johnson et al., 2011; Liang et al., 2012; Michener and Smolke, 2012). In 
the last decade, the field of synthetic biology has emerged to combine biology 
with engineering design and construction principles to develop biological systems 
3with more novel and complex function. Some examples include genetic oscillators 
(Elowitz and Leibler, 2000), logic gates (Win and Smolke, 2008a; Xie et al., 2011; 
Moon et al., 2012) and other architectures that can perform computation and 
allow for programmed gene expression, aiming to begin to recapitulate the 
sophisticated circuitry of natural systems. This synthetic biology promises to 
allow for powerful solutions to address many of society’s most pressing needs. 
1.1.1 Metabolic engineering 
Among our most daunting challenges is to be able to supply chemicals needed 
for modern life in ways that are safe, efficient, and sustainable. Our ancestors first 
began using the yeast Saccharomyces cerevisiae to produce ethanol almost 9,000 
years ago (McGovern et al., 2004). Similarly, molds that produce antibiotics have 
been used to treat infection since at least 2,000 BCE (Forrest, 1982). Even with 
modern science and chemical synthesis, some 63% of new drugs are still derived 
from natural products (Newman and Cragg, 2007), and many are produced by 
methods involving extraction from natural organisms, a testament to the potential 
of biology for synthesis of chemicals and materials. However, natural microbial 
organisms did not evolve to produce compounds useful to humans, or do to so in 
a way that is convenient for large-scale industrial production.  
 In recent years, the emerging field of metabolic engineering has had large 
success in engineering microbes to produce valuable compounds not naturally 
produced in these organisms. Microbial synthesis has several attractive traits 
when contrasted with traditional manufacturing methods. Because many 
reactions can be done enzymatically inside cells, microbial production may often 
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obviate or reduce the need for toxic chemicals. Biosynthetic pathways can be 
engineered to take as starting material renewable, easily acquired products, such 
as sugar or biomass. Traditional chemical synthesis methods, by contrast, often 
require oil and gas products, which are not renewable, often subject to 
geopolitical and geographic difficulties, and in many instances harmful to people 
or to the environment. To date, researchers have engineered metabolic pathways 
to produce the anti-malarial drug precursor artemisinic acid (Ro et al., 2006); 
benzylisoquinoline alkaloids (Hawkins and Smolke, 2008); biofuels from alkanes 
(Schirmer et al., 2010), n-butanols (Bond-Watts et al., 2011), higher alcohols 
(Atsumi et al., 2008; Dellomonaco et al., 2011), terpenes (Peralta-Yahya et al., 
2011), and fatty acids (Steen et al., 2010; Dellomonaco et al., 2011), as well as many 
other important compounds. While many of these pathways have yet to be scaled 
and developed as economically viable industrial production processes, it is clear 
that as synthetic biology technologies mature further, metabolic engineering is 
poised to replace traditional manufacturing for the production of many important 
substances. 
1.1.2 Cellular and tissue engineering 
Advances in synthetic biology have also been used to reprogram human cells. 
One promising avenue to combat many diseases is adoptive T-cell therapy, in 
which immune cells can be reprogrammed to seek out and destroy certain cells, 
such as cancerous ones (June, 2007). Bacteria, too, have been reprogrammed to 
specifically invade cancer cells (Anderson et al., 2006). Recent advances also allow 
for editing genomes to repair damaged genes, or confer novel functionality, by 
5engineered nucleases. These nucleases generally consist of a DNA-binding 
domain fused to a DNA-cleaving domain that can perform specific cleavage at a 
target DNA sequence, allowing for gene deletions, gene corrections, or addition of 
heterologous genes (Urnov et al., 2010). One recent effort demonstrated using 
transcription activator-like effector nucleases (TALENs), a type of engineered 
nucleases, to replace a dysfunctional copy of a gene with a functional one in cells 
derived from a patient (Osborn et al., 2013).  
Another exciting avenue for correcting aberrant cell behavior is developing 
stem cells to replaced damaged tissues. Embryonic stem cells (ESCs) have been in 
clinical trials for several years for the treatment of age-related macular 
degeneration (AMD) (Advanced Cell Technology, Inc.), spinal cord injury (Geron, 
Inc.), and metastatic melanoma (California stem cell, Inc.), among others. More 
recently, researchers have been able to create induced pluripotent stem cells 
(iPSCs) from terminally differentiated cells by forced expression of a set of 
proteins that confer pluripotency on previously terminally differentiated cells, 
followed by inducing their differentiation into desired cell types, usually by 
expression of yet more protein factors (Ferreira and Mostajo-Radji, 2013). Earlier 
this year, the first clinical trial was approved for using iPSCs to replace damaged 
epithelium in patients with AMD (Institute for Biomedical Research and 
Innovation and RIKEN, Japan). There continues to be great excitement about the 
potential for ESCs and iPSCs for the treatment of many debilitating ailments 
(Kondo et al., 2012).  
  
6 
1.1.3 Future prospects for synthetic biology 
Future applications of synthetic biology will no doubt continue to approach 
the sophistication and myriad functionality observed in natural systems. Or, 
perhaps, open the door to new possibilities not found in nature. Researchers have 
been incorporating non-natural amino acids into proteins for several years, 
granting properties not possible in nature (Johnson et al., 2011). There has also 
been much progress in creating an orthogonal genetic code, which would allow 
greater utilization of these non-natural amino acids to create engineered proteins 
with novel functionality (Anderson et al., 2004). Other work has generated 
organisms with de novo synthetized DNA (Gibson et al., 2010). Taken together, 
these developments suggest that the field is poised to coopt the diversity of 
biological possibility to address many pressing needs.  
At present, however, there are several bottlenecks that stall progress. 
Although the cost of DNA sequencing has been dropping at a rate exceeding 
Moore’s law, from almost $6,000 per megabase in 2000 to less than five cents now, 
gene synthesis is still relatively expensive, decreasing only 20-fold in the same 
period (Quail et al., 2012). Implementing new biological designs often requires 
significant time and resources, while evaluating design performance may be 
unfeasibly slow, for instance, when no method exists for detecting a desired 
metabolite. And of course, there are still significant shortcomings in our current 
understanding of the underlying biology, limiting our ability to design more 
sophisticated systems. 
Many of the current examples in both metabolic engineering and human cell 
engineering consist of identifying useful genes—whether a working copy of a 
7mutated gene, genes that direct cellular specialization, or genes encoding 
enzymes that produce a valuable compound—and moving those genes into the 
cell of interest where they become constitutively expressed. However, many 
metabolic pathways involve intermediates that can react to form undesirable 
products, or enzymes that are expressed when they are either not needed or when 
they can act on an unintended substrate, limiting yield, and resulting in the 
production of undesired byproducts. Natural systems have evolved schemes to 
regulate their genes in complex ways. Although relatively new, synthetic 
dynamic gene control systems have already greatly increased yields of some 
engineered metabolic pathways in E. coli (Farmer and Liao, 2000; Zhang et al., 
2012). These efforts, however, have generally consisted of coopting existing 
proteins that modulate their activity in response to changing levels of a specific 
input molecule, and are not generally easy to reengineer to sense and modulate 
their activity in response to different molecular inputs. Further, there are very few 
examples of synthetic gene-regulatory systems that can operate in eukaryotes, 
where many pathways involving enzymes that require glycosylation, membrane 
localization, and other eukaryotic processing steps are constructed (Nasser et al., 
2003). 
In cellular and tissue engineering, efforts are similarly limited by the relative 
dearth of synthetic gene-regulatory technologies that can operate in mammalian 
cells, in contrast with the complex gene networks that operate in natural systems 
to allow for proper development and cell function. These natural gene control 
systems involve regulation of many genes temporally, spatially, and in response 
to various signals, and can operate at many of the steps involved in gene 
8expression. A brief survey of the cellular processes involved in the expression of a 
mature protein is warranted to set in context the players and timescales involved 
in the life of a transcript, and how these would allow for the development of 
effective synthetic gene control systems. 
1.2 Overview of gene expression in eukaryotes 
 The process by which genes gain functionality by becoming mature proteins 
involves myriad steps each of which may provide opportunities for synthetic 
regulation. Efforts in our laboratory and others have often focused on the yeast S. 
cerevisiae, a model organism whose genetics are thoroughly understood and 
amenable to manipulation, that recapitulates many of the features of higher 
eukaryotes, and that is generally nonhazardous to human health, labeled as 
“Generally Regarded as Safe” (GRAS) by the Food and Drug Administration. 
These considerations have led to the widespread use of yeast as a microbial 
production host. For simplicity, I will focus my discussion on this organism, while 
keeping in mind that many of the processes described below are similar in higher 
eukaryotes such as humans. 
1.2.1 General characteristics of S. cerevisiae 
 Baker’s yeast is a unicellular eukaryotic organism that can exist in haploid or 
diploid form. Haploids can be of mating type a or !. Two haploids of different 
mating types can undergo meiosis to generate a diploid cell. Both diploid and 
haploid organisms can reproduce by mitosis, called budding. Under some 
conditions, diploids can sporulate and generate four haploid cells. Cells are 
spherical or ovoid, with an average diameter of 5-10 "m, and an average nuclear 
9diameter of 1.9 "m (Jorgensen et al., 2007). As with other eukaryotes, yeast cells 
cycle among G1, S, G2, and M phases. In rich media, doubling time is 1.5 hr, 
which equates to a growth rate of 0.46/hr.  
1.2.2 Genetics of S. cerevisiae 
 Haploid S. cerevisiae contains 16 chromosomes ranging in size from 230 kb to 
1,532 kb with some 13 million base pairs encoding more than 6,000 open reading 
frames (Broach et al., 1991). Its mitochondria contain approximately 78.5 kb of 
DNA that encode some 15% of the enzymes active in that organelle (Ibid.). 
Additionally, the circular 2" plasmid containing 6.3 kb of DNA is present at 
approximately 20 to 50 copies in most organisms (Ibid.). Some S. cerevisiae cells can 
be infected by any of several dsDNA viruses (Ibid.). Many research laboratories, 
including ours, primarily derive their yeast strains from the widely studied 
haploid W303! strain (MAT!; leu2-3, 112; trp1-1; can1-100; ura3-1; ade2-1; his3-
11,15), which lends itself to genetic manipulation through various means. 
Exogenous genes can be integrated into a desired chromosomal locus by 
homologous recombination, allowing for different levels of expression depending 
on the integration site. Genes can also be added in 2"-like plasmids, which are 
present at approximately 20 to 50 copies per cell, or in centromeric plasmids, 
present at 1 copy per cell (Tschumper and Carbon, 1983). Generally, expression 
level and variability within a population is higher from plasmids than for 
chromosomal integrations, and particularly so for high-copy plasmids (Romanos 
et al., 1992). The selection marker used can have a significant effect on expression 
levels both for chromosomally integrated and plasmid-encoded genes. 
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1.2.3 Transcription of mRNA 
In eukaryotes such as S. cerevisiae, messenger RNAs (mRNAs) are transcribed 
from DNA by RNA Polymerase II (PolII), a holoenzyme composed of 10-12 
subunits, which along with accessory proteins binds promoters and proceeds to 
transcribe the gene until transcription termination. The first step in the process, 
transcription initiation, is thought to be stochastic (Frieda and Block, 2012) and 
dependent on the abundance of the specific transcription factors that bind their 
cognate promoter, with an average occupancy of ~0.078 PolII  complexes per kb 
of gene (Pelechano et al., 2010). Once properly docked and bound by transcription 
factors, PolII elongation appears to be deterministic and to proceed at ~20-25 
nt/sec (Edwards et al., 1991; Pelechano et al., 2010), although this rate can vary 
throughout the cell cycle. After elongation, termination appears to take 70±41 sec 
(Frieda and Block, 2012). mRNA steady-state levels average 15,000 mRNA 
transcripts per cell, or approximately 2.5 mRNAs per each of the 6,000 genes in S. 
cerevisiae (Jelinsky and Samson, 1999), although this number can vary among 
different genes. Most genes produce 2-30 mRNAs per hour (Pelechano et al., 
2010). 
1.2.4 mRNA folding and activity 
An mRNA can adopt different three-dimensional structures which in many 
cases can be important in determining how that mRNA acts, binds other factors, 
and is processed to yield functional proteins (Dethoff et al., 2012a). The problem 
of predicting which structures a given RNA sequence being transcribed will 
adopt during its lifetime depends on factors such as transcriptional speed, 
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thermodynamic and kinetic determinants, the binding of other entities such as 
ligands or protein chaperones, energy barriers to structural rearrangements, and 
the timescales and binding factors involved in transcription, RNA processing, 
translation, and mRNA decay. This problem may be very difficult, if not 
impossible, to solve with current tools. A simpler, though still not trivial, problem 
is to predict equilibrium secondary structures for a given sequence, for which 
methods with relatively high accuracy have been developed (Zuker, 2003; Reuter 
and Mathews, 2010). However, it remains important to keep in mind how this 
approximation differs from how RNA folding occurs in vivo.  
There has long been evidence that certain RNA structures can fold during 
transcription (Boyle et al., 1980; Kramer and Mills, 1981). Consider, for instance, 
that RNA domains can form on the timescale of seconds (Bothe et al., 2011; 
Dethoff et al., 2012a, 2012b). With transcriptional elongation occurring at some 20-
25 nt/sec, termination lasting on the order of many tens of seconds, and other 
processing steps lasting up to several minutes (Oeffinger and Zenklusen, 2012), it 
is clear that equilibrium folding does not paint a complete picture of in vivo 
folding. Although predictive algorithms for co-transcriptional folding have been 
developed (Proctor and Meyer, 2013), it remains difficult to evaluate their 
accuracy. Many of these tools rely on simplifying assumptions such as constant 
transcriptional speed and absence of RNA-binding factors, which are inaccurate 
for many important applications. While more research is needed to flush out these 
details, RNA structure prediction remains much more accurate than protein 
structure prediction, and continues to be important in determining how RNAs 
fold and affect gene expression. 
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1.2.5 mRNA processing and export 
Before a transcript can be translated, many processing steps occur during and 
after transcription, including 5’ capping, 3’ cleavage, polyadenylation, and 
nuclear export. Splicing, although widespread in higher eukaryotes, is not 
prevalent in yeast, where only some 5% of the total 6,000 genes contain introns 
(Lewin, 2008), and thus will be ignored in this discussion.  
Many of these processing steps are mediated by modifications to the C-
terminal domain of the large subunit of Pol II, the C-terminal domain (CTD), 
which aids in recruiting other factors yielding a dynamic messenger 
ribonucleoprotein complex (mRNP) undergoing constant modification and 
quality control as its being transcribed (Egloff and Murphy, 2008; Buratowski, 
2009). During transcription, the cap-binding complex (CBC) attaches to the 5’ end 
of the mRNP and remains attached until export to the cytoplasm. The 3’ end of 
the mRNP undergoes 3’ splicing, polyadenylation, and binding by poly(A)-
binding proteins such as Pab1p and Nab2p, which also remain attached until 
export to the cytoplasm.  
Nuclear export of mRNP occurs through the nuclear pore complex (NPC). 
First, the mRNP must diffuse from its location in the nucleus to one of the some 
119 NPCs on the nuclear membrane (Maul and Deaven, 1977). Estimates of the 
diffusion coefficients for mRNPs vary depending on the transcript and research 
methodology, but many studies list values close to 1 "m2/sec (Grünwald et al., 
2011). An average yeast nucleus has a volume of ~2.9 "m3 (Jorgensen et al., 2007), 
yielding transit times to the nuclear membrane on the order of seconds. Once at 
the NPC, transport of most mRNPs is mediated by the Mex67-Mtr2 complex 
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(Segref et al., 1997). A recent study of mRNA transport in live cells showed that 
the entire process of binding to the NPC, transport, and release takes 
approximately 180 msec (Grünwald and Singer, 2010), although again these times 
may be different for different transcripts.  
1.2.6 Translation 
Once in the cytoplasm, transcripts can begin to generate proteins. Translation 
initiation begins by removal of the CBC from the 5’ cap and binding of eukaryotic 
initiation factors (eIFs) 4G and 4E and associated proteins.  eIF4 interacts with 
Pabp1, generating a circular “activated” mRNP (Hinnebusch and Lorsch, 2012). 
The activated mRNP is then bound by the 40S ribosomal subunit and associated 
factors to form a pre-initiation complex (PIP), which scans for a start codon. 
Initiation efficiency is partly a function of mRNA secondary structure near the 
start codon (Kozak, 2005), and is thought to be rate-limiting (Preiss and Hentze, 
2003). In yeast, most genes contain a relatively unstructured consensus sequence 
“aAaAaAATGTCt” (with the start codon shown in bold and less-conserved bases 
in lower case) which increases translation initiation efficiency (Hamilton et al., 
1987). 
Once the start codon is found, the 60S ribosomal subunit and associated 
factors bind and translation elongation can begin. Multiple ribosomes can be 
active on a given transcript, with an average occupancy of 0.64 ribosomes per 100 
nt of coding RNA (Arava et al., 2003). On average, translation elongation 
proceeds at 7-8 amino acids per second per ribosome, although this speed 
depends on the availability of transfer RNAs (tRNAs) cognate to the codons in the 
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transcript, with rare codons leading to inefficient translation (Ikemura, 1982). 
Once the ribosome proceeds to the stop codon, elongation release factors (eRFs) 1 
and 3 and associated proteins mediate the release of the nascent peptide from the 
ribosome (Mugnier and Tuite, 1999).  
Protein abundance in yeast ranges from approximately 50-106 proteins per cell, 
with an average of about 2,000 (Ghaemmaghami et al., 2003). Synthesis rates 
generally fall in the range of 1.8-5.4/hr (Von der Haar, 2008), and protein half-
lives average 43 min (Belle et al., 2006). 
1.2.7 mRNA decay 
 For mature transcripts in the cytoplasm, decay can occur either 5’ →3’ or 3’ 
→5’. For both cases, the process begins with deadenylation until a transcript 
contains fewer than ten 3’ terminal adenosines. In yeast, the primary decay 
mechanism involves 5’ decapping by the enzymes Dcp1 and Dcp2 followed by 5’ 
→3’ degradation by the exoribonuclease Xrn1 (Parker and Song, 2004). 
Alternatively, following deadenylation, a transcript can be degraded 3’ →5’ by the 
cytoplasmic exosome. Other degradation pathways clear mRNAs with premature 
termination codons, ones that lack a stop codon, or ones that stall due to strong 
RNA secondary structure, termed nonsense mediated decay (NMD), non-stop 
decay (NSD), and no-go decay (NGD), respectively (Shoemaker and Green, 2012). 
Degradation can also occur in the nucleus, where mRNAs lacking a 5’ cap are 
readily degraded 5’ →3’ by the exoribonuclease Rat1, and to some extent by Xrn1, 
while those lacking polyadenylation can be readily degraded 3’ →5’ by the 
nuclear exosome (Houseley and Tollervey, 2009). These processes mediate mRNA 
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half-lives on the order of tens of minutes, with a mean of 11 min (Miller et al., 
2011). 
1.2.8 Overview of kinetics of gene expression 
 All in all, a picture emerges of the timescales, concentrations, and organization 
of the main biological molecules involved in gene expression. Many of these 
processes are evolutionarily conserved among eukaryotes, if with some important 
differences. Mammalian cells often require more extensive mRNA processing, 
including widespread splicing, with 95-100% of genes containing introns and 
being alternatively spliced (Conze et al., 2010). Additionally, mammalian cells are 
much larger than yeast, usually with cellular and nuclear volumes 2-10 times 
larger than yeast’s (Rosenbluth et al., 2006). These differences account for longer 
diffusion times, and often slower processing steps. Mammalian cell doubling 
times, for example, are typically greater than approximately 16hrs (Kumei et al., 
1987), 11 times longer than yeast’s. Below, Figure 1.1 summarizes the entire 
process of gene expression in yeast.  
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Figure	  1.1	  Overview	  of	  gene	  expression	  in	  yeast	  
Gene	  expression	  in	  yeast	  involves	  several	  steps	  with	  characteristic	  time	  scales	  and	  component	  
localization-­‐specific	  processing.	  The	  diagram	  shows	  DNA	  being	  transcribed	  by	  PolII	  and	  accessory	  
factors,	  generating	  a	  dynamic	  mRNA-­‐protein	  complex	  that	  translocates	  to	  the	  cytoplasm	  where	  
further	  processing	  and	  translation	  yields	  functional	  proteins.	  Average	  timescales	  for	  relevant	  
processes	  in	  yeast	  are	  shown	  in	  green.	  Molecules	  are	  not	  drawn	  to	  scale.	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1.3 Synthetic gene-regulatory systems in eukaryotes 
For many potential applications of synthetic biology, it would be desirable to 
tailor gene expression to cellular characteristics. For example, a useful biological 
device might be instructed with reprogramming cells that display aberrant 
behavior while not disrupting other cells in a way that would cause pathology. 
Another useful device might be one that can induce expression of a particular 
metabolic enzyme only when it is needed, allowing for less waste, and better 
yields.  
Generally, what we would want in a gene control platform is to be able to 
regulate the expression of a desired output gene, in response to relevant changes 
of an input signal, to such a degree that it would cause a physiologically useful 
phenotypic change. For example, if a particular cell contains high levels of a 
cancer biomarker, an ideal device might increase expression of a protein that 
reprograms the cell a non-malignant state. Or, if metabolite “K” has reached high 
levels, begin expressing the perhaps growth-limiting enzyme “Kase,” and letting 
the cell to grow unburdened when “Kase” is not needed. Additionally, depending 
on the intended application, some important characteristics of such a system are 
listed in Figure 1.2.  
 Several kinds of synthetic eukaryotic gene control systems have been 
developed that operate at different steps of gene expression. Below, I will give a 
brief description of the more commonly used gene regulation platforms that 
constitute the current state of the art.   
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Characteristic	   Definition	  
Modularity	   The	  system	  could	  be	  easily	  redesigned	  to	  respond	  to	  different	  inputs	  and	  
act	  on	  different	  outputs,	  often	  by	  recombining	  component	  “modules”	  that	  
confer	  input	  or	  output	  function.	  	  
Scalability	   The	  output	  level	  of	  the	  system	  could	  be	  scaled	  to	  cover	  the	  range	  over	  
which	  a	  change	  in	  output	  corresponds	  to	  a	  change	  in	  phenotype.	  Similarly,	  
the	  sensitivity	  to	  changes	  in	  input	  would	  be	  scaled	  to	  cover	  the	  range	  over	  
which	  the	  relevant	  change	  in	  input	  occurs.	  
Uniformity	   In	  a	  population	  of	  cells,	  the	  system	  would	  behave	  similarly	  enough	  among	  
all	  the	  cells	  such	  that	  perturbations	  due	  to	  genetic	  noise	  or	  other	  
unintended	  factors	  would	  not	  significantly	  affect	  phenotypes.	  
Orthogonality	   The	  system	  would	  not	  significantly	  affect	  the	  performance	  of	  other	  gene	  
networks,	  including	  both	  other	  synthetic	  networks,	  and	  the	  cell’s	  existing	  
networks.	  
Simplicity	   The	  components	  of	  the	  system	  would	  not	  be	  too	  taxing,	  either	  by	  
consuming	  too	  many	  cellular	  resources,	  or	  by	  necessitating	  too	  much	  
effort	  to	  generate	  or	  incorporate	  genetically	  into	  the	  desired	  cells.	  	  
Figure	  1.2	  Important	  ideal	  characteristics	  of	  an	  ideal	  synthetic	  gene-regulatory	  system	  
1.3.1. Control over gene insertion 
 One obvious method of synthetic gene expression control is to introduce 
desired genes—often constitutively expressed—only into the cells one wishes to 
reprogram. Such an approach has been employed clinically, but only on certain 
accessible and somewhat isolated tissues such as the eye and skin (Kondo et al., 
2012). For reprogramming cancerous cells distributed deep and throughout the 
body, such a strategy is not viable. Similarly, there are no methods to constrain 
presence of a gene only to the subset of cells growing in a fermenter that have at a 
given time point accumulated sufficient levels of a given intermediate metabolite. 
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1.3.2 Transcriptional control by protein factors 
A commonly used strategy for synthetic gene expression control has been to 
control transcription. Generally, such systems involve a synthetic transcription 
factor (TF) that contains a DNA-binding domain, an activation (or repression) 
domain, and a ligand-binding domain that alters activity of one of the other 
domains. In one early example, the E. coli tetracycline repressor (tetR) was fused 
to the activation domain of the herpes simplex virus protein 16 (VP16) to generate 
a tetracycline trans activator (tTA) (Gossen and Bujard, 1992). Binding of the tetR 
domain to tet operator sequences placed adjacent to a minimal promoter drove 
expression of a downstream target gene in response to expression of tTA. 
Addition of tetracycline, which modulates the conformation and activity of tTA, 
lowered gene expression by up to five orders of magnitude. Variants of tTA have 
been engineered with various gene expression responses, including turning gene 
expression “on” in response to tetracycline. Similar systems that respond to 
several other ligands have also been developed or adopted from natural systems. 
One group has developed modular binding domains composed of zinc-finger 
proteins that allow for orthogonal regulation of different target genes by different 
TF variants with various regulatory dynamics, while still retaining a large 
dynamic range on the order of approximately 100 fold (Khalil et al., 2012).  
Although TF-based systems generally display high-fold changes in expression 
in response to their ligand, they have several disadvantages. First, they generally 
require the expression of a heterologous transcription factor protein, which may 
cause immune responses in humans, limiting the application of these systems in 
clinical settings. Even in yeast, expression of such proteins can often be associated 
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with toxicity or growth defects. Second, although there are examples of 
reengineering these synthetic TFs to respond to novel ligands (Collins et al., 2005), 
these efforts have so far only been successful in evolving sensitivity to close 
homologues of the original ligands, usually while still maintaining some 
sensitivity to the original ligand. It remains difficult to engineer TFs that respond 
specifically to wholly novel entities.  And third, often these systems are difficult to 
tune to different performance parameters, such as different output levels. 
1.3.3 Transcriptional control by RNA switches 
 Transcriptional control can also be achieved by non-protein factors. One group 
evolved an RNA sequence capable of strongly activating transcription from a 
specific promoter, and later attached an aptamer to allow allosteric control 
(Buskirk et al., 2004). Although this work demonstrated up to 10-fold activation 
upon ligand addition, the riboswitch is specific to the promoter to which it was 
evolved, and it may be nontrivial to develop riboswitches that bind other 
promoters. Further, the mechanism through which this design works has not been 
fully elucidated. And lastly, the design calls for expression of heterologous 
proteins, which may limit application in human cells due to immunogenicity 
concerns. 
1.3.4 Post-transcriptional control by RNAse III switches 
Many groups have developed strategies to control gene expression at 
processing steps that occur after transcription initiation. For example, a number of 
regulatory elements have been developed that act through modulating cleavage 
of a synthetic substrate by different endogenous RNase III enzymes. In yeast, one 
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strategy involved integrating small-molecule aptamers into synthetic substrates to 
the S. cerevisiae RNase III, Rnt1p (Babiskin and Smolke, 2011b). The study showed 
up to a 6-fold change in the expression of a reporter gene upon ligand addition. 
The design is modular in that it can regulate any transgene, and can potentially be 
generalized to other ligands to which a suitable aptamer exists or can be 
generated. Of course, the platform is not portable to other eukaryotes, including 
humans, which do not normally express Rnt1p. 
However, similar strategies can be employed in mammalian cells, where the 
activity of other RNase III enzymes on synthetic substrates can be used for 
synthetic gene control. One group incorporated an aptamer to a small molecule 
into a synthetic short hairpin RNA (shRNA) to modulate cleavage by Dicer in 
response to ligand addition. Dicer cleavage directed subsequent silencing of a 
target gene, allowing for ~4-fold modulation of target gene expression (An et al., 
2006). A similar example involved integrating a protein aptamer into a synthetic 
shRNA to control expression of anti-apoptotic genes, achieving ~10-fold 
modulation of cell death (Saito et al., 2011). Independently, our laboratory has 
demonstrated a similar strategy by integrating small-molecule aptamers into 
synthetic microRNAs (miRNAs) to modulate Drosha processing and subsequent 
silencing of a target gene (Beisel et al., 2011). This study was able to achieve ~5-
fold modulation of gene expression in response to the presence of the small-
molecule ligand. Another group has coupled a small-molecule aptamer to an 
allosteric ribozyme whose cleavage modulates the release of a primary miRNA 
(pri-miRNA). Release of the pri-miRNA allows for Drosha processing and gene 
silencing of a target gene. This study achieved ~3-fold changes in expression of a 
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reporter gene (Kumar et al., 2009). These designs do not depend on the expression 
of heterologous proteins, making them attractive candidates to control gene 
expression in human cells for the treatment of disease. However, so far they 
exhibit relatively modest dynamic ranges, and there is concern that these small 
RNA silencers may affect expression of partly homologous off target genes 
(Birmingham et al., 2006). 
The examples just described can detect proteins and small molecules and 
modulate activity of small RNA silencers. However, levels of endogenous small 
RNA silencers can also serve as markers of cell state. One group designed a 
strategy to detect endogenous miRNA expression patterns to regulate expression 
of pro-apoptotic proteins, achieving ~10-fold modulation of cell death between 
cell types that express different miRNAs (Xie et al., 2011). However, these designs 
rely on the expression of heterologous proteins, which may cause immunogenic 
concerns. 
1.3.5 Ribozyme switches 
 Another strategy developed in our laboratory involves integrating small-
molecule aptamers into a self-cleaving hammerhead ribozyme placed in the 3’ 
untranslated region (UTR) of a transgene in yeast (Win and Smolke, 2007), 
allowing for allosteric regulation of gene expression. The platform has been 
further developed for complex logical computation (Win and Smolke, 2008a) and 
high-throughput in vivo tuning and in vitro characterization (Kennedy et al., 2012; 
Liang et al., 2012). Further, because the platform does not make use of any 
proteins that may only be endogenous to specific organisms, it is applicable for 
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use in human cells, and has been employed to control T-cell proliferation in 
cultured mammalian cells and live mice (Chen et al., 2010). One drawback is that 
so far, dynamic ranges have been modest, with a maximum of ~10 fold (Liang et 
al., 2012). However, the design has been shown to be modular in responding to 
different small molecule inputs. 
1.3.6 Translational control 
 RNA regulation has also been applied to control translation. One early 
example involved small-molecule aptamers placed in the 5’ UTR of a gene in 
mammalian cells that allowed for modulation of gene expression in response to 
small-molecule binding (Werstuck and Green, 1998). Another group 
demonstrated a similar approach with protein aptamers, and applied the design 
to regulate pro-apoptotic genes, achieving ~10-fold modulation of cell death in 
response to the presence of the protein ligand (Saito et al., 2011). These designs 
are promising in that they involve no heterologous proteins. However, as with 
other RNA-based systems described here, the ~10-fold dynamic range is modest. 
Further, because the system depends on blocking ribosome progress along a 
transcript, its behavior depends on the characteristics of the aptamer–ligand 
interaction. With some aptamers, even unbound by ligand, strong secondary 
structure can significantly lower gene expression, casting doubt on how well such 
a design can be employed to respond to different inputs.  
1.3.7 Evaluation of current platforms 
The synthetic gene-regulatory strategies described above can be evaluated by 
how they approach the desired characteristics described in Figure 1.2, namely, 
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modularity, scalability, uniformity, orthogonality, and simplicity. Of course, the 
real evaluation criterion is how well a given synthetic regulatory scheme could be 
employed for an application of interest, which for different applications might 
depend on one set of characteristics more than another.  
 In general, RNA-based platforms have greater modularity. It is generally 
significantly easier to find an RNA sequence that can bind and switch in response 
to a ligand of interest than to do the same for a protein. While researchers have 
long been generating RNA aptamers to ligands of interest de novo (Ellington and 
Szostak, 1990; Tuerk and Gold, 1990), often with high affinity and specificity, such 
is not the case for generating de novo protein domains that bind ligands of interest. 
This shortcoming is perhaps a technological one. Proteins have 21 naturally 
occurring amino-acid building blocks whereas RNAs only have four naturally 
occurring nitrogenous base building blocks. This difference allows for far wider 
potential functional diversity of proteins. In addition, there are over 500 known 
amino acids (Wagner and Musso, 1983), which as technologies to incorporate 
unnatural amino acids develop further could significantly expand the possibilities 
for protein function. There are, by contrast, only about a dozen known non-
natural nitrogenous bases that can be incorporated into RNA, and there are no 
existing methods to incorporate these into living systems (Yang et al., 2010).  
 Still, at present, protein engineering as a field is far from being able to design 
proteins that can regulate gene expression in a modular way. Even if such were 
the case, for applications in mammalian cells that can address the many 
significant problems we face in the area of human health, there is still the problem 
of immunogenicity. Heterologous proteins often cause significant immune 
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responses. While in the distant future it may be possible to somehow elude this 
problem, whether by modulating human immune system development or 
activity, or by developing a method to design proteins that do not elicit such a 
response, today this remains an important roadblock. 
RNA-based gene control systems have their own shortcomings. Broadly 
generalizing, RNA systems tend to be more modular, owning to the relative ease 
of developing RNA aptamers to ligands of interest, and to our currently greater 
ability to predict RNA structure, at least relative to predicting protein structure. 
Further, most RNAs do not cause an immune response in mammalian cells, 
making RNA a compelling design substrate for gene control systems designed for 
applications in human health. However, they tend to exhibit lower dynamic 
ranges. While different researchers describe dynamic range in different ways—
with some using activities of enzymes to describe gene expression levels and 
some using fluorescent reporter proteins—most RNA-based gene control 
strategies self-describe at most ~10-fold modulation of gene expression. Is killing 
90% of a cancer enough?  
While certainly for some applications 10-fold may be sufficient, there is a clear 
need to develop viable gene control strategies with greater dynamic ranges. It is 
unclear why most of these RNA-based systems have lower dynamic ranges than 
most widely used TF-based systems. However, one possibility may have to do 
with the number of species that are being regulated. As shown in Figure 1.3, 
there is a large difference in average number of molecules per cell among DNA, 
RNA, and protein species. This “amplification” occurs in going from mRNAs to 
proteins, where abundance jumps 1,000-fold. It is reasonable to assume that 
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control at the “reverse-bottleneck” of transcription may generally more 
dramatically affect the change in protein expression than control after this 
“reverse-bottleneck.” 
Mean	  copy	  
number	  
Mean	  
half-­‐life	  
Mean	  
synthesis	  rate	  
References	  
DNA	   1	   -­‐-­‐	   ~0.46/hr	  
mRNA	   ~2.5	   ~11	  min	   ~2-­‐30/hr	   (Jelinsky	  and	  Samson,	  1999)	  
(Pelechano	  et	  al.,	  2010)	  
Protein	   ~2,000	   ~43	  min	   ~1.8-­‐5.4/hr	   (Belle	  et	  al.,	  2006)	  
(Ghaemmaghami	  et	  al.,	  2003)	  
(Von	  der	  Haar,	  2008)	  
Figure	  1.3	  Parameters	  of	  various	  types	  of	  biological	  molecules	  in	  yeast	  
Biological	  molecule	  parameters	  can	  vary	  among	  the	  more	  important	  classes	  found	  in	  cells.	  DNA,	  
mRNA,	  and	  protein	  average	  levels	  and	  half-­‐lives	  can	  differ	  by	  orders	  of	  magnitude.	  Values	  given	  
represent	  average	  parameters	  for	  a	  single	  gene	  and	  its	  mRNA	  and	  protein	  products	  in	  a	  typical	  
haploid	  yeast	  cell	  growing	  under	  normal	  conditions.	  	  
Another possibility may involve energy barriers to structural rearrangements. 
While both proteins and mRNAs exist under a certain structural dynamism 
owning to thermal noise and kinetic or electrostatic interactions with other 
molecules, it is important to note that thermodynamic barriers to more dramatic 
structural changes differ between proteins and RNAs. For one, proteins can 
contain covalent bonds between distal amino acids, while RNAs only form 
hydrogen bonds between distal bases. Additionally, certain protein folds such as 
the alpha helix or beta sheet are extremely stable, while typical RNA folds often 
consist of relatively short runs of base pairing. In RNA structural rearrangements, 
step-wise one base-pair rearrangements can result in low energy barriers. A 
recent study analyzed several riboswitches and proposed folding paths between 
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their functional conformations, finding most step-wise energy barriers to be 
relatively small, generally ~1-2 kcal/mol (Quarta et al., 2012). With lower barriers 
to structural rearrangement, it is reasonable to assume that there may be lower 
barriers for a given regulatory RNA to switch between an active and an inactive 
conformation, even when one of those conformations is stabilized by binding to a 
ligand. Thus, it may be that RNA regulators spend more time sampling both 
active and inactive conformations, leading to lower differences between their 
active and inactive states, and thus lower-fold regulation of gene expression. 
Some of the riboswitches developed in our laboratory, for instance, are designed 
to switch between active and inactive conformations that differ by energies ~1.2 
kcal/mol, only twice the thermal energy available at 30°C, which in an 
equilibrium Boltzmann distribution would translate to only a ~7-fold difference in 
the frequency at which these states are populated.  
Still another possible factor to explain the modest observed dynamic range for 
synthetic RNA-based gene control versus the high dynamic range for synthetic 
protein-based gene control may have to do with cooperativity. It is known that 
many transcription factors cooperate to generate a more digital response to 
changing signal levels (Banerjee, 2003; Chang et al., 2006), often resulting in 
greater sensitivity to signal induction and greater changes in output activity 
(Bialek and Setayeshgar, 2008). Many other examples of proteins whose activity is 
cooperative, in that it changes in a more digital manner in response to increasing 
levels of an input, have been widely studied, such as the classic example of 
cooperativity of hemoglobin-oxygen binding. While cooperativity has also been 
observed in RNAs (Vaidya et al., 2012), and it may be possible to design 
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regulatory RNAs that are also cooperative, the phenomenon remains primarily a 
characteristic of proteins, and particularly of those involved in the protein-based 
gene control strategies described above.  
Today, it remains of general interest in the field of synthetic biology, and 
particularly in applications of synthetic biology in eukaryotes such as yeast and 
mammalian systems, to develop more modular and better-performing gene 
control strategies. Developing of these technologies would expand our prospects 
to reengineer life to solve some of society’s most onerous challenges.   
1.4 Scope of thesis 
This thesis describes expanding the capabilities of synthetic gene control in 
eukaryotes. We take as a starting point a synthetic ribozyme switch platform 
previously developed in our laboratory (Win and Smolke, 2007, 2008b) which 
displays many promising attributes. Among these are our ability to employ the 
platform for complex computation schemes (Win and Smolke, 2008b), established 
methods to rapidly tune and characterize device properties (Kennedy et al., 2012; 
Liang et al., 2012), and known design principles stemming from our ability to 
predict RNA structure-function relationships (Win and Smolke, 2007). The 
platform has also been demonstrated in mammalian cells (Chen et al., 2010; Wei et 
al., 2013), where likely absence of immunogenic response stemming from its 
expression promise powerful applications in gene therapy. In metabolic 
engineering, too, the platform has proven effective in the development of novel 
enzymes by correlating enzyme activity to an easily detected signal (Michener 
and Smolke, 2012).  Lastly, the platform is designed to be modular, in that it can 
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regulate any transgene, or any endogenous gene by 3’ UTR replacement (Babiskin 
and Smolke, 2011b). Moreover, established methods to generate RNA aptamers to 
molecules of interest suggest the device can be employed to take as input any of a 
wide array of molecules, in stark comparison to TF-based control platforms, 
which are not generally generalizable to different inputs. 
Thus far, however, the ribozyme switch platform has not been shown to 
respond to protein inputs. In Chapter 2, we demonstrate the first known instance 
of ribozyme-mediated, protein input-responsive gene regulation in eukaryotic 
cells. We describe efforts to integrate protein aptamers directly into a self-cleaving 
ribozyme at several integration points. Although this strategy does not seem to 
elicit protein input-mediated gene regulation, the associated studies demonstrate 
how different modifications of the ribozyme structure affect cleavage activity, 
informing further development of ribozyme switches. We find success in using 
strand displacement as a strategy to achieve protein input-responsive ribozyme 
switches, achieving up to 4-fold modulation of target gene expression in response 
to the presence of a protein input. In vitro characterization shows evidence that 
the observed gene expression modulation stems from protein input-mediated 
modulation of ribozyme cleavage activity. We further show that the platform is 
translatable to mammalian cells. Lastly, we conclude with thoughts about the 
general applicability of the platform and mechanistic details of its gene-regulatory 
activity. 
Having further demonstrated the modularity of our ribozyme switch platform 
for controlling gene expression, we next turn to its range of output gene 
modulation. So far, eukaryotic riboswitch platforms have generally had modest 
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dynamic ranges of output gene expression modulation, generally on the order of 
10 fold, and often in response to induction by high concentrations of input 
molecules (Liang et al., 2011). TF-based systems, while largely exhibiting modular 
and high-fold regulation of output gene expression (Khalil et al., 2012), exhibit 
limitations with respect to their adaptability to respond to different input 
molecules, limiting their widespread use for synthetic biology. In Chapter 3, we 
demonstrate a TF-riboswitch gene amplifier in eukaryotes. This platform 
combines the modular-input characteristics of ribozyme switch-mediated 
regulation with the high-fold, modular output characteristics of TF-mediated gene 
expression control. Our amplifier platform allows for as much as 20-fold 
regulation of output gene expression in response to input signal. EC50 values are 
more than 4 times lower than in our best-performing non-amplifier ribozyme 
switches, and maximal “ON” state gene expression approaches the highest 
expression levels commonly observed in yeast.   
In Chapter 4, we conclude with future directions for our ribozyme switch and 
amplifier platforms. We discuss further device development and characterization, 
as well as applications in gene therapy and metabolic engineering.  Collectively, 
the work included in this thesis extends the capabilities of ribozyme switches, a 
powerful tool for synthetic gene control, promising more sophisticated 
customizable applications of synthetic biology. 
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Chapter 2 
Development of protein-responsive ribozyme 
switches in eukaryotic cells 
Abstract	  
As	  synthetic	  biology	  continues	  to	  develop	  promising	  solutions	  to	  some	  of	  society’s	  most	  pressing	  needs,	  
the	  dearth	  of	  technologies	  that	  can	  correlate	  cell	  state	  to	  programmed	  gene	  expression	  in	  eukaryotic	  
organisms	  hinders	  the	  development	  of	  more	  sophisticated	  applications.	  Although	  some	  platforms	  have	  
been	  developed	  to	  detect	  and	  program	  gene	  expression	  in	  response	  to	  changing	  protein	  levels,	  current	  
systems	  either	  can	  only	  operate	  in	  certain	  organisms,	  risk	  off-­‐target	  effects,	  or	  are	  not	  generally	  modular	  
or	  scalable.	  Here,	  we	  demonstrate	  the	  use	  of	  synthetic	  self-­‐cleaving	  riboswitches	  to	  detect	  changes	  in	  input	  
protein	  levels	  and	  convey	  that	  information	  into	  programmed	  gene	  expression	  in	  eukaryotic	  cells.	  We	  
demonstrate	  both	  up-­‐	  and	  down-­‐regulation	  of	  levels	  of	  an	  output	  transgene	  by	  more	  than	  4	  fold	  in	  
response	  to	  rising	  input	  protein	  levels,	  with	  maximal	  output	  gene	  expression	  approaching	  the	  highest	  
levels	  observed	  in	  yeast.	  In	  vitro	  experiments	  demonstrate	  protein-­‐dependent	  riboswitch	  activity	  
modulation.	  We	  further	  demonstrate	  the	  platform	  in	  mammalian	  cells.	  Our	  riboswitch	  devices	  do	  not	  
depend	  on	  special	  input	  protein	  activity,	  and	  can	  be	  tailored	  to	  respond	  to	  any	  input	  protein	  to	  which	  a	  
suitable	  RNA	  aptamer	  can	  be	  developed.	  This	  platform	  can	  potentially	  be	  employed	  to	  regulate	  expression	  
of	  any	  transgene	  or	  any	  endogenous	  gene	  by	  3’	  UTR	  replacement,	  allowing	  for	  more	  complex	  cell	  state-­‐
specific	  reprogramming	  with	  applications	  in	  gene	  therapy	  and	  cellular	  engineering.
Partly	  adopted	  from	  d’Espaux,	  L.D.,	  Kennedy,	  A.B.,	  Vowles,	  J.V.,	  Bloom,	  R.J.,	  and	  Smolke,	  C.D.	  (2013).	  
Development	  of	  protein-­‐responsive	  ribozyme	  switches	  in	  eukaryotic	  cells.	  In	  preparation
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2.1 Introduction 
Synthetic biology continues to develop into a promising avenue for addressing 
some of our most pressing challenges, including in areas of disease, energy, and 
the sustainable production of chemicals. For many potential applications, cue-
specific control over expression of certain genes would allow greater 
sophistication and functionality. Constraining gene expression to desired cell 
states would further enable treatments in which expression of therapeutic genes 
must be targeted to diseased cells, avoiding undesired side effects (Zhou et al., 
2004). It would also further develop our ability to use engineered cells to repair 
desired tissues. For example, recent efforts have employed embryonic stem cells 
(ESCs) and induced pluripotent stem cells (iPSCs) to generate new tissues, often 
by forced expression of transcription factors (TFs) that confer pluripotency, or 
allow for differentiation into desired cell types (Ferreira and Mostajo-Radji, 2013). 
However, there remain concerns about unregulated stem cell TF expression 
potentially leading to cancer (Kondo et al., 2012). For many of these examples, 
being able to regulate gene expression precisely in response to cues regarding the 
cellular state would allow for safer and more effective therapeutic strategies.  
Cells can differ dramatically in their properties. A one base-pair mutation 
leading to a small difference in the expression of one protein may differentiate a 
normal cell from one that would develop into a lethal cancer (Hollstein et al., 
1991). Differences among different cell types, or cell states, are often determined 
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by the levels of a handful of molecules. For example, many cancers can be 
identified by altered levels of known protein markers (Weigel and Dowsett, 2010; 
Newton et al., 2012). iPSCs are often created by altering expression of just four 
transcription factors (Yu et al., 2007). Proteins, generally, are often important 
identifiers of a cell’s state. There are some 50 million total proteins in a typical 
eukaryotic cell (Futcher et al., 1999), with an average concentration of ~1"M 
(Ghaemmaghami et al., 2003; Lu et al., 2007), with specific proteins varying by 
sometimes many orders of magnitude among different cellular states. Being able 
to detect these differences and convey that information into desirable phenotypic 
changes in eukaryotic cells is a pressing need in gene therapy and other areas of 
cellular engineering. 
RNA has recently emerged as a powerful platform for the development of 
synthetic gene control strategies owning partly to its versatility and modularity. 
Standard protocols allow for the development of RNA sequences that can 
recognize and tightly bind other molecules, including small molecules and 
proteins (Ellington and Szostak, 1990; Tuerk and Gold, 1990). RNA structure 
prediction is often very accurate (Zuker, 2003; Dimitrov and Zuker, 2004; Reuter 
and Mathews, 2010; Proctor and Meyer, 2013), facilitating the design of molecular 
switches where a structural change affects function. Additionally, many 
functional noncoding RNA classes have been identified, including self-cleaving 
ribozymes present in all domains of life (Perreault et al., 2011), special folds that 
undergo specific cleavage by RNases, including microRNAs, short hairpin RNAs, 
and other substrates (Lamontagne and Abou Elela, 2007), and metabolite-
responsive riboswitches (Winkler et al., 2004), among many others. Lastly, 
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synthetic RNAs expressed in living cells do not normally elicit immune responses, 
while synthetic transcription factors usually do. Inspired by these characteristics, 
researchers have developed strategies to allosterically regulate gene expression 
using synthetic functional RNA, although generally these platforms only operate 
in prokaryotes, and few respond to protein inputs (Liang et al., 2011).   
Protein-responsive regulation has been achieved in mammalian cells by 
placing aptamers within introns to modulate alternative splicing (Culler et al., 
2010), although this strategy has not been demonstrated in other eukaryotes, 
where alternative splicing pathways can be absent or different from mammals. 
Further, gene expression modulation has been relatively modest, under 4 fold. 
Another strategy involved placing protein aptamers in the 5’ untranslated region 
(UTR) of a reporter gene (Saito et al., 2011), although this strategy can lead to low 
basal gene expression due to strong 5’ UTR secondary structure, and may not be 
generalizable to other protein inputs. The same group has also demonstrated 
placing protein aptamers within synthetic short hairpin RNA (shRNA) substrates 
which can modulate how these shRNAs are processed and lead to gene silencing 
(Saito et al., 2011; Kashida et al., 2012). However, the strategy is not generalizable 
to eukaryotes that do not employ shRNA-mediated gene silencing, and reports of 
shRNA-mediated off-target effects (Birmingham et al., 2006) cast doubt on 
widespread use of these technologies, even in mammals. 
Our laboratory has previously developed a ribozyme switch platform by 
integrating small-molecule aptamers into a self-cleaving hammerhead ribozyme 
placed in the 3’ UTR of a heterologous gene in yeast (Win and Smolke, 2007), 
allowing for allosteric regulation of gene expression in response to changing 
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levels of small molecules. These switches are composed of a small-molecule 
aptamer coupled to a hammerhead ribozyme through a transmitter sequence. The 
transmitter is designed to allow for two primary switch conformations that differ 
in whether they contain properly folded ribozyme or aptamer domains (Figure 
2.1). In switch “ON” designs, aptamer and ribozyme folds are mutually exclusive 
within each primary conformation. Ligand–aptamer binding stabilizes the 
aptamer-active conformation, diminishing the fraction of riboswitches in the 
ribozyme-active conformation, lowering cleavage activity. In the “OFF” design, 
aptamer and ribozyme folds are mutually inclusive, so that aptamer–ligand 
binding stabilizes the ribozyme-active conformation, increasing cleavage activity. 
When these switches are incorporated in the 3’ UTR of a target gene, cleavage 
activity leads to transcript degradation and loss of expression. Ligand-induced 
modulation of cleavage activity allows for control over gene expression levels.  
The ribozyme switch platform has been further developed for complex logical 
computation (Win and Smolke, 2008a) and high-throughput in vivo tuning and in 
vitro characterization (Kennedy et al., 2012; Liang et al., 2012). It has also been 
demonstrated in mammalian cells, where it allowed for control of engineered T-
cell proliferation in cultured cells and in live mice (Chen et al., 2010). Platform 
behavior in mammalian cells can be predicted by activity in yeast, allowing for 
rapid device development and tuning (Wei et al., 2013). Because of its modular 
construction, the platform can be employed to regulate any transgene, or any 
endogenous gene by 3’ UTR replacement (Babiskin, 2011). However, so far its 
inputs have been limited to small-molecule inducers.  
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Figure	  2.1	  Design	  of	  in	  vivo	  hammerhead	  ribozyme	  switch	  platform	  
A	  hammerhead	  ribozyme	  is	  a	  naturally	  occurring	  RNA	  sequence	  that	  can	  undergo	  rapid,	  site-­‐
specific	  self-cleavage	  (site	  indicated	  by	  red	  scissors).	  A	  synthetic	  ribozyme	  switch	  couples	  this	  
ribozyme	  to	  a	  ligand-binding	  aptamer	  sequence	  (black	  bases)	  through	  engineered	  transmitter	  
sequences	  (pink	  bases).	  The	  switch	  is	  encoded	  in	  the	  3’	  untranslated	  region	  of	  a	  target	  gene,	  in	  
this	  case	  GFP,	  and	  upon	  transcription	  in	  eukaryotic	  cells	  is	  designed	  to	  exist	  in	  two	  primary	  
conformations.	  In	  this	  example	  of	  an	  “ON”	  switch,	  conformations	  are	  mutually	  exclusive	  in	  
whether	  they	  contain	  a	  ribozyme-active	  domain	  or	  an	  aptamer-folded	  domain.	  Ribozyme-­‐
active	  conformations	  undergo	  cleavage,	  leading	  to	  rapid	  exonuclease-mediated	  transcript	  
degradation,	  and	  loss	  of	  GFP	  expression.	  Binding	  of	  a	  ligand	  (orange	  circle)	  stabilizes	  the	  
aptamer-folded	  conformation,	  which	  in	  this	  case	  is	  diminishes	  cleavage	  activity,	  and	  allows	  for	  
greater	  GFP	  expression.	  Thus,	  increased	  levels	  of	  ligand	  lead	  to	  target	  gene	  expression	  being	  
turned	  “ON.”	  In	  “OFF”	  switch	  designs	  (not	  shown),	  ribozyme-active	  and	  aptamer-folded	  
domains	  are	  mutually	  inclusive.	  In	  the	  absence	  of	  ligand,	  transcripts	  primarily	  do	  not	  undergo	  
cleavage,	  but	  do	  so	  when	  ligand	  binding	  stabilizes	  the	  aptamer-folded	  and	  ribozyme-active	  
conformation.	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This ribozyme switch platform has been further developed for complex logical 
computation (Win and Smolke, 2008a) and high-throughput in vivo tuning and in 
vitro characterization (Kennedy et al., 2012; Liang et al., 2012). It has also been 
demonstrated in mammalian cells, where it allowed for control of engineered T-
cell proliferation in cultured cells and in live mice (Chen et al., 2010). Platform 
behavior in mammalian cells can be predicted by activity in yeast, allowing for 
rapid device development and tuning (Wei et al., 2013). Because of its modular 
construction, the platform can be employed to regulate any transgene, or any 
endogenous gene by 3’ UTR replacement (Babiskin, 2011). However, so far its 
inputs have been limited to small-molecule inducers.  
Here we further develop the platform to be able to detect and modulate gene 
expression in response to levels of protein inputs. We demonstrate both up- and 
down-regulation of levels of an output transgene by more than 4 fold in response 
to rising input protein levels, with maximal output gene expression approaching 
levels from no-ribozyme controls. In vitro experiments demonstrate protein-
dependent switch activity modulation. We further demonstrate the platform in 
mammalian cells. Our ribozyme switch devices do not depend on special input 
protein activity, and can be generalizable to any input protein to which a suitable 
RNA aptamer can be developed. This platform can potentially be employed to 
regulate expression of any transgene, or any endogenous gene by 3’ UTR 
replacement, allowing for more complex cell state-specific reprogramming with 
applications in cellular engineering and gene therapy. 
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2.2 Results and Discussion 
2.2.1 Integrating MS2 aptamers into ribozymes by direct coupling 
We constructed an initial set of protein-responsive ribozyme switches by 
integrating known protein aptamers directly into a hammerhead ribozyme. We 
initially chose a direct-integration strategy because proteins, being much larger 
than small molecules, might by their sheer size lead to significant disruption of 
the cleavage-active ribozyme conformation. It has long been known that in 
addition to conserved sequence and secondary structure elements, hammerhead 
ribozymes require tertiary interactions between peripheral loops for in vivo 
activity (De la Peña et al., 2003; Khvorova et al., 2003). Thus, we theorized that 
protein binding near these regions might be sufficient to modulate ribozyme 
cleavage without the need for a separate transmitter domain that would direct 
secondary structure changes in the ribozyme. By obviating the need to engineer 
transmitter sequences, the direct-integration strategy may allow for a more 
modular plug-and-play architecture that might be generalizable to other protein 
aptamers.  
We designed two classes of switches, ones in which we integrated aptamers 
directly on loop I of the hammerhead ribozyme, which we call dc1 for “direct 
coupling into loop I” (Figure 2.2), and ones in which we integrated aptamers into 
stem III just below the catalytic core, which we call dc3 for “direct coupling into 
stem III” (Figure 2.3). We decided to integrate aptamers into loop I because with 
the relatively slow speed of transcription, at ~20 nt/sec (Edwards et al., 1991; 
Pelechano et al., 2010), loop I would be fully formed more than one full second 
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before the entire ribozyme is transcribed, allowing extra time for protein binding 
before the fully-transcribed riboswitch can begin cleaving. We theorized that 
protein binding during switch transcription might funnel subsequent folding 
rearrangements to ligand-bound conformations that would not readily form in 
the absence of protein, serving as a kinetic switch (Quarta et al., 2012). We also 
decided to try integrating inside stem III itself because this integration point 
would be closest to the catalytic core, potentially having a greater chance of 
disrupting cleavage activity after protein binding. For both classes of switches, 
dc1 and dc3, we integrated aptamers to the bacteriophage MS2 coat protein (MS2) 
previously shown to bind their cognate protein with high affinity (Parrott et al., 
2000; Horn et al., 2004).   
We first examined whether these riboswitches can bind MS2 protein via a 
Biacore surface plasmon resonance (SPR) assay, in which we coupled non-
cleaving, mutated-core versions of our riboswitches to a sensor chip, passed 
various concentrations of MS2 over the chip, and analyzed binding kinetics. We 
found that the aptamers integrated into the ribozymes generally bound their 
cognate protein as well as aptamer alone, some with dissociation constants in the 
tens of nanomolar range (Figure 2.4). Riboswitches with MS2 aptamers integrated 
into stem III, wherein the aptamer terminal loop is replaced by a stem leading into 
the ribozyme core, did not exhibit any binding. This is consistent with the 
previous observation that the bases in this terminal loop of the aptamer 
participate in MS2 binding (Horn et al., 2004), and changing their configuration 
from an open loop into a base-paired structure appears to disallow these protein-
aptamer interactions. 
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Figure	  2.2	  Design	  of	  protein-responsive	  ribozyme	  switch	  by	  direct	  coupling	  into	  loop	  I	  
dc1-­‐type	  protein-­‐responsive	  ribozyme	  switches	  were	  designed	  by	  coupling	  a	  protein	  aptamer	  
(black	  bases)	  directly	  into	  loop	  I	  of	  a	  self-­‐cleaving	  hammerhead	  ribozyme.	  The	  switch	  is	  encoded	  in	  
the	  3’	  untranslated	  region	  of	  a	  target	  gene,	  in	  this	  case	  GFP,	  and	  upon	  transcription	  in	  eukaryotic	  
cells	  is	  designed	  to	  exist	  in	  two	  primary	  conformations.	  In	  the	  ribozyme-­‐active,	  aptamer-­‐unbound	  
conformation,	  Loop	  1-­‐loop	  2	  interactions	  and	  cleavage-­‐necessary	  structural	  elements	  allow	  for	  
ribozyme	  self-­‐cleavage	  activity.	  In	  the	  aptamer-­‐bound	  conformation,	  disruption	  of	  cleavage	  
structural	  elements	  decreases	  cleavage.	  Increased	  levels	  of	  protein	  ligand	  (blue	  barrel)	  may	  
increase	  the	  fraction	  of	  transcripts	  in	  ribozyme-­‐inactive	  conformations.	  Ribozyme	  cleavage	  leads	  
to	  rapid	  exonuclease-­‐mediated	  transcript	  degradation,	  and	  lower	  reporter	  gene	  expression.	  These	  
switches	  are	  designed	  to	  be	  “ON”-­‐switches	  in	  that	  increased	  levels	  of	  protein	  ligand	  decrease	  
cleavage	  activity	  and	  turn	  gene	  expression	  “ON.”	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Figure	  2.3	  Design	  of	  protein-responsive	  ribozyme	  switch	  by	  direct	  coupling	  into	  stem	  III	  
dc3-­‐type	  protein-­‐responsive	  ribozyme	  switches	  were	  designed	  by	  coupling	  a	  protein	  aptamer	  
(black	  bases)	  directly	  in	  stem	  III	  of	  a	  self-­‐cleaving	  hammerhead	  ribozyme.	  The	  switch	  is	  encoded	  in	  
the	  3’	  untranslated	  region	  of	  a	  target	  gene,	  in	  this	  case	  GFP,	  and	  upon	  transcription	  in	  eukaryotic	  
cells	  is	  designed	  to	  exist	  in	  two	  primary	  conformations.	  In	  the	  ribozyme-­‐active,	  aptamer-­‐unbound	  
conformation,	  structural	  elements	  allow	  for	  ribozyme	  self-­‐cleavage	  activity.	  In	  the	  aptamer-­‐bound	  
conformation,	  disruption	  of	  these	  cleavage-­‐necessary	  structural	  elements	  decreases	  cleavage.	  
Increased	  levels	  of	  protein	  ligand	  (blue	  barrel)	  may	  increase	  the	  fraction	  of	  transcripts	  in	  
ribozyme-­‐inactive	  conformations.	  Ribozyme	  cleavage	  leads	  to	  rapid	  exonuclease-­‐mediated	  
transcript	  degradation,	  and	  lower	  reporter	  gene	  expression.	  These	  switches	  are	  designed	  to	  be	  
“ON”-­‐switches	  in	  that	  increased	  levels	  of	  protein	  ligand	  decrease	  cleavage	  activity	  and	  turn	  gene	  
expression	  “ON.”	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KD	  (nM)	   ka	  (1/M-­‐s)	   kd	  (1/s)	  
M1	   9.99	   7,338,000	   0.07334	  
M2	   0.12	   23,890,000*	   0.00284*	  
M3	   0.07	   27,730,000*	   0.00190*	  
dc1M1	   17.10	   3,815,000	   0.06524	  
dc1M2	   0.02	   151,400,000*	   0.00230*	  
dc1M3	   0.36	   16,100,000*	   0.00572*	  
dc3M1	   n.b.	   n.b.	   n.b.	  
dc3M2	   n.b.	   n.b.	   n.b.	  
dc3M3	   n.b.	   n.b.	   n.b.	  
Figure	  2.4	  Kinetic	  parameters	  of	  direct-coupling	  MS2	  ribozyme	  switch	  in	  vitro	  protein	  binding	  
Dissociation	  constant	  (KD),	  association	  (ka)	  and	  dissociation	  (kd)	  rates	  for	  selected	  aptamer	  and	  
ribozyme	  switch	  constructs	  binding	  purified	  MS2	  (see	  Materials	  and	  Methods)	  show	  that	  
aptamers	  integrated	  into	  ribozymes	  directly	  bind	  cognate	  protein	  similarly	  to	  aptamer	  alone.	  M1–
3	  are	  different	  aptamers	  to	  MS2	  (Parrott	  et	  al.,	  2000).	  dc1M1–3	  are	  switches	  into	  which	  
corresponding	  MS2	  aptamers	  were	  integrated	  into	  loop	  I.	  dc3M1–3	  are	  switches	  into	  which	  
corresponding	  MS2	  aptamers	  were	  integrated	  into	  stem	  III.	  Some	  constructs	  showed	  no	  binding	  
(n.b.)	  to	  MS2.	  All	  switches	  contained	  a	  mutated	  core	  that	  abolishes	  cleavage	  activity,	  allowing	  for	  
clear	  identification	  of	  protein	  binding	  and	  dissociation	  events.	  *Some	  values	  of	  kd	  and	  ka	  might	  be	  
masked	  by	  mass	  transfer	  limitations,	  which	  would	  not	  affect	  KD	  values	  (Karlsson,	  1999).	  	  
Next, we sought to determine whether these switches maintained in vivo 
cleavage activity when modified with these aptamers. We chose to initially 
develop our devices in yeast, owning to strong observed correlation between 
ribozyme switch behavior in mammalian cells and S. cerevisiae (Wei et al., 2013), 
allowing for rapid device development and characterization in this latter model 
organism. We cloned our switches into the 3’ untranslated region (UTR) of a GFP 
reporter expression construct and expressed these plasmids in yeast. The data 
indicate that cleavage was generally robust, in some cases as efficient as from wild 
type ribozyme, achieving as much as 98% reduction in GFP levels (Figure 2.5). In 
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general, for the same aptamer, integration through stem III elicited greater 
cleavage activity than through loop I. This observation is perhaps due to the fact 
that with stem III integration, the generally base-paired structure of the aptamers 
stabilizes the formation of the stem, helping to bring together the otherwise most 
distal segments in the ribozyme fold, serving as a molecular clamp. Loop I 
integration, by contrast, might in some cases interfere with tertiary interactions 
between loops I and II required for in vivo activity (De la Peña et al., 2003; 
Khvorova et al., 2003).  
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Figure	  2.5	  Basal	  expression	  of	  transcripts	  with	  3'	  UTR	  direct	  integration	  MS2	  riboswitches	  
When	  cloned	  in	  the	  3’	  UTR	  of	  a	  reporter	  GFP	  gene,	  direct-­‐ coupling,	  MS2	  aptamer-­‐ containing	  
ribozyme	  switches	  strongly	  abrogate	  GFP	  expression	  in	  yeast.	  RSV	  is	  wild	  type	  ribozyme;	  dc1M1–3	  
are	  ribozymes	  into	  which	  MS2-­‐binding	  aptamers	  M1–3	  were	  cloned	  at	  an	  integration	  point	  on	  
loop	  I;	  dc3M1–3	  contain	  the	  same	  aptamers	  in	  stem	  III.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  
a	  non-­‐aptamer,	  non-­‐cleaving	  control.	  Error	  bars	  indicate	  one	  standard	  deviation	  from	  the	  mean.	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Knowing that in general these switches cleave efficiently and can bind their 
cognate proteins relatively tightly, we next examined whether protein binding 
was able to modulate cleavage activity in vivo. We expressed plasmids bearing 
our switches in the 3’ UTR of GFP alongside either empty control plasmids or 
plasmids expressing MS2 to observe what effect MS2 expression had on switch 
activity. Generally, the switches did not show any significant modulation of GFP 
expression abrogation when co-expressed with MS2, with at most ~0.48-fold 
change in expression, compared to ~0.20-fold for RSV (Figure 2.7).  
We hypothesized that protein localization might play an important role in 
protein-responsive ribozyme switch regulation. Whereas small molecules such as 
theophylline can likely diffuse readily through the nuclear pore channel, protein 
transport between the nucleus and the cytoplasm is protein sequence-dependent, 
with localization signals dictating protein levels among different cellular 
compartments (Pemberton et al., 1998). For switches being transcribed in the 
nucleus and spending up to several minutes undergoing mRNA processing and 
nuclear transport before reaching the cytoplasm (Oeffinger and Zenklusen, 2012), 
absence of nuclear-localized ligand may have drastic consequences. For a kinetic 
switch in which ligand-binding would funnel subsequent folding trajectories into 
ligand-bound conformations (Quarta et al., 2012), absence of that ligand in the 
nucleus would result in little to no allosteric regulation. And regardless of 
switching mechanism, measured ribozyme cleavage kinetics at physiological 
conditions (Kennedy et al., 2012; Liang et al., 2012) predict a significant fraction of 
transcripts cleaved even after a few minutes, leaving little chance for cytoplasmic 
protein-mediated GFP expression modulation (Figure 2.6).  
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Figure	  2.6	  Modeled	  cleavage	  kinetics	  at	  times	  after	  ribozyme	  transcription	  
Ribozyme	  cleavage	  was	  modeled	  at	  different	  time	  points	  by	  single	  exponential	  decay	  using	  
cleavage	  constants	  of	  ribozyme	  and	  ribozyme	  switch	  devices	  determined	  experimentally	  at	  
physiologically	  relevant	  conditions	  (Kennedy	  et	  al.,	  2012;	  Liang	  et	  al.,	  2012).	  The	  wild	  type	  
ribozyme	  cleaves	  at	  4.3/min.	  Mean	  mRNA	  half-­‐life	  in	  yeast	  is	  ~11	  min	  (Jelinsky	  and	  Samson,	  1999).	  
Thus, we created an MS2 variant containing an N-terminal nuclear localization 
signal (NLS) and co-expressed it alongside our switches. Generally, NLS-MS2 co-
expression did not lead to any evidence of switch cleavage inhibition. If anything, 
GFP levels decreased (Figure 2.7), although this was also the case for the dc3 
constructs previously demonstrated not to bind MS2, suggesting that any GFP 
expression modulation is not mediated by MS2–aptamer binding.  
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Figure	  2.7	  MS2	  direct-coupling	  ribozyme	  switch	  response	  to	  MS2	  protein	  variants	  
Direct-coupling,	  MS2	  aptamer-containing	  ribozyme	  switches	  appear	  not	  to	  modulate	  GFP	  
expression	  in	  response	  to	  cognate	  MS2	  expression	  in	  yeast.	  Selected	  devices	  were	  cloned	  in	  the	  
3’	  UTR	  of	  a	  reporter	  GFP	  plasmid	  and	  expressed	  alongside	  an	  empty	  control	  or	  vectors	  expressing	  
nuclear-localized	  (NLS-)	  MS2	  or	  MS2.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  non-aptamer,	  
non-cleaving	  control.	  Error	  bars	  indicate	  one	  standard	  deviation	  from	  the	  mean.	  For	  samples	  
showing	  increased	  GFP	  levels	  upon	  MS2	  variant	  expression,	  activation	  ratios	  (ARs)	  are	  reported	  
as	  ratios	  of	  mean	  GFP	  levels	  from	  device	  constructs	  co-expressed	  with	  MS2,	  divided	  by	  mean	  GFP	  
levels	  from	  the	  same	  device	  when	  co-expressed	  with	  an	  empty	  control.	  For	  devices	  showing	  
decreased	  GFP	  levels	  upon	  MS2	  variant	  expression,	  repression	  ratios	  (RRs)	  are	  reported	  as	  the	  
negative	  ratios	  of	  mean	  GFP	  levels	  from	  device	  constructs	  co-expressed	  with	  an	  empty	  control,	  
divided	  by	  mean	  GFP	  levels	  from	  the	  same	  device	  when	  co-expressed	  with	  MS2.	  RSV	  is	  the	  wild	  
type	  ribozyme	  which	  contains	  no	  MS2	  aptamer.	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2.2.2 Integrating p50 aptamers into ribozymes by direct coupling 
 To determine whether the lack of observed switching from direct-coupling 
MS2 ribozyme switch designs was specific to these particular aptamer–protein 
pairs being suboptimal, or due to our design strategy not allowing for switching, 
we next decided to construct switches to a different protein following the direct-
coupling strategy. We integrated into the same locations on loop I and stem III an 
aptamer to Nuclear Factor-#B p50 subunit (p50) previously shown to bind 
cognate protein with high affinity in vitro and in vivo (Cassiday and Maher, 2003; 
Wurster et al., 2009). Again, we used the SPR assay to characterize switch–p50 
interactions in vitro and observed very tight binding, with dissociation constants 
in the low nanomolar range, generally 10- to 100-fold lower than for our MS2 
aptamers (Figure 2.8).  
KD	  (nM)	   ka	  (1/M-­‐s)	   kd	  (1/s)	  
K1	   2.57	  ±	  0.16	   339,000	  ±	  80,050	   0.000870	  ±	  0.000150	  
dc1K1	   2.34	  ±	  0.19	   1,12,000	  ±	  50,870	   0.00262	  ±	  0.000350	  
dc3K1	   7.37	  ±	  0.32	   310,000	  ±	  70,100	   0.00185	  ±	  0.000780	  
Figure	  2.8	  Kinetic	  parameters	  of	  p50 direct-coupling	  ribozyme	  switch	  in	  vitro	  protein	  binding	  	  
Dissociation	  constant	  (KD),	  association	  (ka)	  and	  dissociation	  (kd)	  rates	  for	  selected	  aptamer	  and	  
ribozyme	  switch	  constructs	  binding	  purified	  p50	  (see	  Materials	  and	  Methods)	  show	  that	  aptamers	  
integrated	  into	  ribozymes	  directly	  bind	  cognate	  protein	  similarly	  to	  aptamer	  alone.	  K1	  is	  an	  
aptamer	  to	  p50.	  dc1K1	  is	  a	  ribozyme	  into	  which	  K1	  was	  were	  integrated	  into	  loop	  I.	  dc3K1	  is	  a	  
ribozyme	  into	  which	  p50	  aptamer	  K1	  was	  integrated	  into	  stem	  III.	  All	  ribozyme	  switches	  contained	  
a	  mutated	  core	  that	  abolishes	  cleavage	  activity	  allowing	  for	  clear	  identification	  of	  protein	  binding	  
and	  dissociation	  events.	  
 We then examined whether these integration points maintained in vivo 
cleavage activity by cloning our devices into the 3’ UTR of a reporter GFP 
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plasmid. We observed higher GFP expression, and presumably lower levels of 
cleavage, than from the MS2-responsive ribozyme switches (Figure 2.9). For 
example, dc1K1 stood out in displaying no evidence of cleavage activity. We had 
chosen our integration point on loop I based on previous experiments with a 
theophylline aptamer which found that this integration point was the best option 
for maintaining cleavage, with only four times less cleavage activity than the wild 
type ribozyme (Kennedy and Smolke, unpublished results). However, seeing that 
this was far from the case for our p50 aptamer, we investigated other integration 
points on loop I, and found that many allowed for more efficient cleavage (Figure 
2.9). While it is unclear why different aptamers coupled into different loop I 
integration points disturb ribozyme activity to different extents, it may have to 
do with the different aptamer sequences interacting differently with the 
peripheral loop I–loop II tertiary interactions. 
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Figure	  2.9	  p50	  direct-coupling	  ribozyme	  switch	  basal	  in	  vivo	  expression	  
When	  cloned	  in	  the	  3’	  UTR	  of	  a	  reporter	  GFP	  gene,	  direct-­‐coupling,	  p50	  aptamer-­‐containing	  
ribozyme	  switches	  strongly	  abrogate	  GFP	  expression	  in	  yeast.	  RSV	  is	  wild	  type	  ribozyme,	  dc1K1	  
contains	  a	  p50	  aptamer	  integrated	  into	  loop	  I,	  dc3K1	  into	  stem	  III.	  dcK2–5	  integration	  sites	  shown	  
on	  left,	  with	  cleavage	  site	  indicated	  by	  a	  red	  scissors.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  
non-­‐aptamer,	  non-­‐cleaving	  control.	  Error	  bars	  indicate	  one	  standard	  deviation	  from	  the	  mean.	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To investigate in vivo switching from these devices, we co-expressed our 
switch-containing GFP plasmids alongside either an empty vector or vectors 
expressing p50 protein variants. Generally, we did not observe any significant 
modulation of GFP levels resulting from expression of p50 or NLS-tagged p50 
(Figure 2.10), suggesting that protein-switch binding did not modulate 
cleavage activity. Other work in our group suggests that binding of proteins to 
cognate aptamers integrated into loop II did not result in cleavage modulation 
in vitro (Kennedy and Vowles, unpublished work), supporting the in vivo 
observations. 
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Figure	  2.10	  p50	  direct-coupling	  ribozyme	  switch	  response	  to	  in	  vivo	  p50	  expression	  
Direct-­‐coupling,	  p50	  aptamer-­‐containing	  ribozyme	  switches	  appear	  not	  to	  modulate	  GFP	  
expression	  in	  response	  to	  cognate	  p50	  expression	  in	  yeast.	  Selected	  devices	  were	  cloned	  in	  the	  3’	  
UTR	  of	  a	  reporter	  GFP	  plasmid	  and	  expressed	  alongside	  an	  empty	  control	  or	  vectors	  expressing	  
NLS-­‐p50	  or	  p50.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control.	  
Error	  bars	  indicate	  one	  standard	  deviation	  from	  the	  mean.	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2.2.3 Integrating MS2 aptamers into ribozymes by strand displacement 
Seeing that our direct-integration strategy failed to produce functional protein-
responsive ribozyme switches, we attempted a new set of switch designs using a 
strand-displacement design strategy previously developed in our laboratory (Win 
and Smolke, 2007, 2008a). As with previously described small-molecule aptamers, 
these switches are composed of an aptamer coupled to a hammerhead ribozyme 
through a transmitter sequence that allows for two primary switch conformations 
that differ in whether they contain properly folded ribozyme or aptamer domains. 
In switch “ON” designs, aptamer and ribozyme folds are mutually exclusive 
within each primary conformation, whereas in the “OFF” design, they are 
mutually inclusive. Aptamer–ligand binding stabilizes the aptamer-containing 
conformation, modulating the fraction of switches containing the ribozyme-active 
conformation, and consequently gene expression levels (Figure 2.11).  
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Figure	  2.11	  Design	  of	  strand-displacement	  ribozyme	  switches	  	  	  
Strand	  displacement	  (sd-­‐type),	  protein-­‐responsive	  ribozyme	  switches	  were	  designed	  by	  coupling	  a	  
self-­‐cleaving	  ribozyme	  to	  a	  protein-­‐binding	  aptamer	  sequence	  (black	  bases)	  through	  engineered	  
transmitter	  sequences	  (pink	  bases).	  The	  switch	  is	  encoded	  in	  the	  3’	  untranslated	  region	  of	  a	  target	  
gene,	  in	  this	  case	  GFP,	  and	  upon	  transcription	  in	  eukaryotic	  cells	  is	  designed	  to	  exist	  in	  two	  
primary	  conformations.	  In	  this	  example	  of	  an	  “ON”	  switch,	  conformations	  are	  mutually	  exclusive	  
in	  whether	  they	  contain	  a	  ribozyme-­‐active	  domain	  or	  an	  aptamer-­‐folded	  domain.	  Ribozyme-­‐active	  
conformations	  undergo	  cleavage,	  leading	  to	  rapid	  exonuclease-­‐mediated	  transcript	  degradation,	  
and	  loss	  of	  GFP	  expression.	  Binding	  of	  the	  protein	  ligand	  (blue	  barrel)	  stabilizes	  the	  aptamer-­‐
folded	  conformation,	  which	  in	  this	  case	  is	  diminishes	  cleavage	  activity,	  and	  allows	  for	  greater	  GFP	  
expression.	  Thus,	  increased	  levels	  of	  ligand	  lead	  to	  target	  gene	  expression	  being	  turned	  “ON.”	  In	  
“OFF”	  switch	  designs	  (not	  shown),	  ribozyme-­‐active	  and	  aptamer-­‐folded	  domains	  are	  mutually	  
inclusive.	  In	  the	  absence	  of	  protein	  ligand,	  transcripts	  primarily	  do	  not	  undergo	  cleavage,	  but	  do	  
so	  when	  protein	  ligand	  binding	  stabilizes	  the	  aptamer-­‐folded	  and	  ribozyme-­‐active	  conformation.	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We designed switches bearing the MS2 aptamer we found to be tightest 
binding based on previous characterization, M3, integrated through various 
transmitter and loop sequences. We refer to these switches by sdMX, where “sd” 
indicates strand displacement and X refers to loop and transmitter modifications. 
sdM-1, -2, and -4 are designed to be “ON” switches, in that aptamer- and 
ribozyme-domain folding are mutually exclusive in the two main conformations, 
and MS2 binding is expected to increase GFP expression. sdM3 is designed to be 
an “OFF” switch, in that aptamer- and ribozyme-domain folding are mutually 
inclusive, and MS2 binding is expected to decrease GFP expression.  
First, we examined whether these switches can bind MS2 through the SPR 
assay. We coupled our switches to a sensor chip under non-cleaving conditions, 
passed various concentrations of MS2 protein over the chip surface, and analyzed 
binding kinetics. The data indicate that most of our switches bind MS2 with high 
affinity, with dissociation constants as low as 6.1 ± 2.4 nM for sdM2 (Figure 2.12). 
KD	  (nM)	   ka	  (1/M-­‐s)	   kd	  (1/s)	  
sdM1	   24.4	  ±	  5.7	   82,250	  ±	  29,810	   0.00189	  ±	  0.00028	  
sdM2	   6.1	  ±	  2.4	   254,600	  ±	  105,800	   0.00138	  ±	  0.00021	  
sdM3	   629.7	  ±	  152.1	   18,800	  ±	  6,864	   0.01115	  ±	  0.00103	  
sdM4	   253.0	  ±	  13.9	   140,300	  ±	  59,600	   0.03889	  ±	  0.01901	  
Figure	  2.12	  Kinetic	  parameters	  of	  strand-displacement	  ribozyme	  switch–protein	  interaction	  from	  SPR	  
Dissociation	  constant	  (KD),	  association	  (ka)	  and	  dissociation	  (kd)	  rates	  for	  selected	  aptamer	  and	  
ribozyme	  switch	  constructs	  containing	  MS2	  aptamers	  integrated	  through	  strand-­‐ displacement	  
transmitter	  sequences	  (sdM1–4)	  bind	  purified	  MS2	  (see	  Materials	  and	  Methods)	  with	  high	  affinity.	  
 53
Next, we examined how MS2 aptamer integration via transmitter sequences  
affected basal cleavage activity. As with the direct-coupling switches, we cloned 
our switches in the 3’ UTR of a GFP reporter gene and measured fluorescence 
levels from the cell population. Generally, GFP levels were reduced compared to 
a non-cleaving control, suggesting robust cleavage activity from our test devices. 
Basal expression levels from the strand-displacement switches were generally 
higher than from the direct-coupling switches. This observation may be explained 
by the fact that strand-displacement switches were designed with transmitter 
sequences that allow the switch molecule to change conformation between two 
primary folds, whereas direct-integration switches are designed for one 
ribozyme-active primary fold. Thus, strand-displacement switches would likely 
sample both ribozyme-active and -inactive conformations, leading to less overall 
cleavage. Regardless, many of the strand-displacement switches exhibited robust 
GFP inhibition in the basal state. For example, sdM2, which was designed by 
replacing loop I from sdM1 with a sequence previously shown to significantly 
increase cleavage activity and lower expression in theophylline-responsive 
ribozyme switches (Kennedy et al., 2012; Liang et al., 2012), showed similarly low 
GFP expression in the context of the MS2 aptamer, approaching that from wild 
type ribozyme (RSV). 
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  Figure	  2.13	  Basal	  expression	  of	  transcripts	  with	  3'	  UTR	  strand-displacement	  MS2	  switches	  
	  When	  cloned	  in	  the	  3’	  UTR	  of	  a	  reporter	  GFP	  gene,	  strand-­‐displacement	  ribozyme	  switches	  
containing	  MS2	  aptamers	  strongly	  abrogate	  GFP	  expression	  in	  yeast.	  RSV	  is	  wild	  type	  ribozyme,	  
sdM1–4	  contain	  MS2	  aptamer	  integrated	  through	  various	  strand-­‐displacement	  transmitter	  
sequences.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control.	  Error	  
bars	  indicate	  standard	  deviation.	  	  
We then examined MS2-mediated regulation of GFP levels by cloning our 
switches in the GFP expression construct and expressing these plasmids alongside 
either a control plasmid, or one expressing MS2. We observed more than 4-fold 
changes in GFP levels upon MS2 expression for both sdM1 and sdM3 (Figure 
2.14). Additionally, GFP expression modulation followed the expected pattern, 
with sdM-1, -2, and -4 having been designed as “ON” switches and increasing 
GFP levels in response to MS2 expression, and sdM3 designed as an “OFF” 
switch, decreasing GFP levels in response to MS2 expression.  
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Figure	  2.14	  MS2	  strand-displacement	  ribozyme	  switch	  response	  to	  in	  vivo	  MS2	  expression	  
Strand-­‐displacement,	  MS2	  aptamer-­‐containing	  ribozyme	  switches	  sdM1–4	  cloned	  in	  the	  3’	  UTR	  of	  
a	  reporter	  GFP	  gene	  exhibit	  MS2	  expression-­‐mediated	  regulation	  of	  GFP	  levels	  in	  yeast.	  RSV	  is	  a	  
wild	  type	  ribozyme	  without	  any	  MS2	  aptamer.	  In	  response	  to	  increased	  MS2	  levels,	  sdM-­‐1,	  -­‐2,	  and	  
-­‐4	  are	  designed	  to	  increase	  GFP	  levels;	  sdM3,	  to	  decrease	  GFP	  levels.	  Mean	  GFP	  levels	  are	  shown	  
normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control.	  Error	  bars	  indicate	  one	  standard	  deviation	  
from	  the	  mean.	  
 To confirm that the observed GFP regulation in vivo was brought about by 
MS2-mediated regulation of switch cleavage activity, we performed in vitro 
experiments to characterize switch cleavage modulation in response to varying 
MS2 levels. We found that the presence of MS2 significantly affected cleavage 
kinetics for the strand-displacement switches, by up to 13-fold (Figure 2.15). 
Further, cleavage modulation followed the expected qualitative trends, with 
“ON” switches exhibiting lower cleavage rates in the presence of MS2, and the 
“OFF” switch higher. A control switch that cleaves at similar rates as our sdM 
switches but which contains a theophylline aptamer (sd2T8) and no MS2 aptamer 
showed no MS2-mediated cleavage modulation, as expected.  
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Figure	  2.15	  In	  vitro	  cleavage	  kinetics	  of	  selected	  ribozyme	  switches	  with	  and	  without	  MS2	  protein	  
Synthesized	  ribozyme	  switches	  incubated	  with	  or	  without	  purified	  MS2	  at	  physiological	  conditions	  
exhibit	  MS2-dependent	  cleavage	  modulation.	  sdT8,	  a	  ribozyme	  containing	  no	  MS2	  aptamer,	  is	  
unaffected	  by	  MS2	  levels.	  kcl	  is	  the	  cleavage	  rate	  as	  predicted	  single	  exponential	  decay	  fitted	  from	  
gel-based	  cleavage	  assays	  (See	  Materials	  and	  Methods).	  
We next sought to explore the mechanism of protein ligand-mediated 
switching in vivo. Riboswitches have been proposed to operate in a spectrum 
within two extremes—kinetic and thermodynamic switching (Quarta et al., 2012). 
For kinetic switching, ligand binding during transcription funnels riboswitch 
folding into aptamer-bound conformations, from which high barriers to structural 
rearrangements disallow transitions into aptamer-unbound conformations and 
their corresponding ribozyme states. In thermodynamic switching, energy 
barriers to structural rearrangements are low, and riboswitches can freely sample 
aptamer-bound and -unbound conformations, with ligand binding stabilizing 
aptamer-bound forms and their corresponding ribozyme states. Where on this 
spectrum our ribozyme switches lie can have important repercussions in how our 
platform can be modified to respond to different protein ligands. Proteins not 
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found in the nucleus, for example, would be unlikely to allow kinetic switching. 
Even for thermodynamic switching, absence of protein ligand during the time 
required for mRNA processing and nuclear export can result in a significant 
fraction of transcripts cleaved (Figure 2.15), making it unlikely that protein 
ligand binding would significantly modulate target gene expression. Regardless 
of switching mechanism, whether our platform necessitates certain localization of 
protein inputs for output gene expression modulation has significant 
ramifications choice of input.  
 To investigate these localization requirements, we constructed MS2 variants 
tagged with N-terminal nuclear localization or export signals (NLS or NES, 
respectively) and co-expressed these along with two of our best-performing 
strand-displacement switches.  We examined what effect input protein 
localization had on ribozyme switch activity (Figure 2.16). Generally, switching 
was less significant from both NES- and NLS-tagged MS2 than from untagged 
protein, the latter expected to localize to both compartments owning to its small 
size (Singer and Grünwald, 2013). Because transcripts spend time both in the 
nucleus and in the cytoplasm prior to and during translation, MS2 expression in 
only one compartment may result in loss of ribozyme cleavage modulation in the 
other compartment, leading to lower overall GFP switching.   
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Figure	  2.16	  MS2	  protein	  localization	  effect	  on	  strand-displacement	  ribozyme	  switch	  response	  
MS2	  aptamer-­‐containing	  ribozyme	  switches	  sdM1	  (“ON”	  switch)	  and	  sdM3	  (“OFF”	  switch)	  cloned	  
in	  the	  3’	  UTR	  of	  a	  reporter	  GFP	  gene	  exhibit	  different	  responses	  to	  co-­‐expression	  of	  MS2	  variants	  
in	  yeast.	  MS2	  was	  tagged	  with	  nuclear	  localization	  signal	  (NLS),	  nuclear	  export	  signal	  (NES),	  or	  no	  
tag.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control.	  Error	  bars	  
indicate	  one	  standard	  deviation	  from	  the	  mean.	  
Interestingly, GFP expression modulation was greater from NLS-MS2 
expression than from NES-MS2 expression. We can interpret this result in various 
ways. A simple explanation would be that NLS-MS2 is expressed at higher levels 
than NES-MS2. Another would be that NLS and NES tags affect MS2 variant-
aptamer binding to different extents. Or, it may be that nuclear MS2 localization 
would more significantly affect device switching via a kinetic mechanism alluded 
to earlier, in which protein binding during transcription funnels ribozyme switch 
folding to aptamer-active conformations and their corresponding ribozyme states. 
Alternatively, it may be that presence of nuclear ligand may lead to greater 
overall switching, whether because transcripts spend a significant amount of time 
in the nucleus, or because the time spent there has a greater effect on ligand-
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mediated switching than time spent in the cytoplasm. Of course, the greater 
switching from NLS-MS2 may have to do with a combination of these factors, and 
we are currently performing additional experiments to further probe these 
questions.  
2.2.4 Translation of strand-displacement ribozyme switches to mammalian cells 
Having demonstrated our platform in yeast, we next explored whether our 
protein-responsive ribozyme switches can operate directly in mammalian cells 
without further modification of switch sequences. To be able to induce input MS2 
expression, we constructed mammalian expression plasmids encoding MS2 
driven by a doxycycline-inducible promoter system. In addition, we placed the 
strand-displacement ribozyme switch in the 3’ UTR of a blue fluorescent protein 
(BFP) controlled by a constitutive promoter. The constructs were co-transformed 
into T-Rex HEK293 cells and MS2 expression induced with doxycycline. The data 
indicate that the switches function in the mammalian cell host to modulate BFP 
expression levels in response to MS2 (Figure 2.17).  
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Figure	  2.17	  MS2-responsive	  strand-displacement	  ribozyme	  switch	  behavior	  in	  mammalian	  cells	  
Strand-displacement,	  MS2	  aptamer-containing	  ribozyme	  switches	  sdM1–4	  cloned	  in	  the	  3’	  UTR	  of	  
a	  reporter	  BFP	  gene	  exhibit	  MS2	  expression-mediated	  regulation	  of	  BFP	  levels	  in	  mammalian	  
cells.	  RSV	  is	  a	  wild	  type	  ribozyme	  without	  any	  MS2	  aptamer.	  In	  response	  to	  increased	  MS2	  levels,	  
sdM-1,	  -2,	  and	  -4	  are	  designed	  to	  increase	  BFP	  levels;	  sdM3,	  to	  decrease	  BFP	  levels.	  Mean	  BFP	  
levels	  are	  shown	  normalized	  to	  a	  non-aptamer,	  non-cleaving	  control.	  Error	  bars	  indicate	  one	  
standard	  deviation	  from	  the	  mean.	  
In general, the gene-regulatory activity of these devices was lower in 
mammalian cells than in yeast as has been previously observed (Chen et al., 2010; 
Wei et al., 2013). For example, wild type ribozyme elicited only 80% abrogation of 
reporter expression compared to ~98% in yeast. As a result, switches with higher 
basal gene expression tended to exhibit lower dynamic ranges in mammalian 
cells, as these basal levels were already close to maximal expression. Conversely, 
sdM2, which in yeast appears to cleave at too high a rate to allow for appreciable 
gene expression in the “ON” state, exhibited better dynamic range in the human 
cell line.  
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2.3 Conclusions 
This work is aimed at expanding the capabilities for synthetic gene regulation 
in eukaryotes. Existing gene control platforms are handicapped owing to possible 
immunogenicity stemming from expression of platform components, organism-
specific functionality, or perhaps most limiting, lack of modularity. These 
characteristics limit their widespread use for developing more sophisticated 
synthetic biological systems for treatment of human disease, and for cellular 
engineering in general. The ribozyme switch platform (Win and Smolke, 2007) 
addresses many of these concerns. However, it has not yet been shown to respond 
to changing levels of proteins, which characterize many changes in cellular state.  
This study resolves this limitation and demonstrates a synthetic ribozyme-
mediated, protein input-responsive gene regulation platform in eukaryotic cells. 
The switches developed here achieved more than 4-fold modulation of target 
gene expression in response to the presence of a protein input in yeast. In vitro 
characterization provided evidence that the observed gene expression modulation 
stems from protein input-mediated modulation of ribozyme cleavage activity. We 
further demonstrated that the platform retains protein-responsiveness in 
mammalian cells. And lastly, preliminary experiments indicate that the platform 
can be used to detect and respond to changes in levels of proteins localized 
throughout the cell, only in the nucleus, or only in the cytoplasm.  
 Interestingly, our initial direct-coupling designs failed to elicit protein-
responsive gene expression control. Although in vitro experiments demonstrated 
that generally dc1 and dc3 designs bound cognate protein effectively, and 
maintained in vivo cleavage activity, we failed to observe any protein-responsive 
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cleavage modulation, either in vitro or in vivo. We demonstrated that certain 
integration points on loop I modulated basal cleavage dramatically. Ostensibly, 
this modulation might be due to the addition of aptamer sequences in certain 
ribozyme locations affecting ribozyme folding, perhaps by disallowing loop I–
loop II interactions required for in vivo activity. This has been suggested by other 
work with theophylline-responsive aptamers located on different loop I 
integration points (Kennedy and Smolke, unpublished results), although different 
integration points with different aptamers affect cleavage activity differently. Still, 
it would seem reasonable to assume that for certain integration points, and certain 
aptamers, addition of aptamer alone to the ribozyme structure might not affect 
cleavage, whereas protein binding would, either by disallowing loop I–loop II 
interactions, or by some other structure modulation effect. However, given that 
different aptamers on the same integration point affect cleavage to different 
extents, and that we failed to observe protein-responsive cleavage modulation 
even for dc1K1–5 which had p50 aptamer integrated on various loop I locations, it 
would seem that this strategy is either flawed, or at the very least not 
generalizable to a given protein–aptamer pair of interest. Similarly, stem III 
integration failed to produce any protein input-mediated change in gene 
expression. And further, the fact that aptamers M1–3 failed to bind cognate 
protein when integrated in stem III makes it difficult to claim that such a design 
might be generalizable. Indeed, many aptamers mediate binding to cognate 
ligands through their unstructured regions—often terminal or internal loops—
making it unlikely that ribozyme integration of these aptamers in such a way that 
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these unstructured regions become part of a stem would maintain binding 
activity. 
 Turning back to our strand-displacement (sd-type) switches, this study 
explored ligand localization-dependence of switch gene-regulatory activity. The 
question is an important one, potentially limiting the range of ligands that the 
ribozyme switch platform may be employed to detect. It also brings up certain 
questions on the molecular design of such switches. In our designs, we have often 
stated that the switches “are designed” to exist in two primary conformations. 
Indeed, secondary RNA structure prediction software generally suggests that sd-
type switches fold into main conformations with similar energies. Often, two 
“primary” folds are indeed predicted, which generally follow our designs. For 
instance, our sdM “ON” switches, as well as sd-type theophylline-responsive 
“ON” switches described earlier, do generally contain one most-favorable 
energetic fold (MFEF) and a slightly less-energetically favorable “nearest 
neighbor.” The MFEF contains a properly folded ribozyme domain, but no 
aptamer domain, whereas the “nearest neighbor” contains a properly folded 
aptamer, but no ribozyme. In our designs, the free energy of this nearest neighbor 
often differs from that of the MFEF by ~2 times the ambient thermal energy, RT. 
In a Boltzmann distribution, this would account for the ribozyme-containing 
MFEF fold being populated at ~7 times the frequency of its aptamer-containing 
neighbor. Binding a ligand with, say, KD~5 nM—similar to the affinity of many of 
our aptamer-protein pairs—would be expected to lower the energy of the 
aptamer-bound conformations by approximately twice RT, making this and the 
ribozyme-containing MFEF equally populated. Such a situation might perhaps 
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explain why generally these switches modulate gene expression by a maximum of 
~10 fold, as do most classes of riboswitches in eukaryotic cells. Although useful 
for some applications, these dynamic ranges continue to be a limitation of 
riboswitch-mediated gene regulation in general. 
 However, there are several ways in which this description differs from the real 
world. First, RNA structure prediction often fails to recapitulate some 
characteristics of real-world folding, such as pseudoknots and other interactions 
including the loop I–loop II tertiary contacts required for in vivo ribozyme activity 
we discussed earlier. Second, it is unclear how these predictions apply to 
populations of mRNA at the single cell level, where mRNA copy number is 
generally low, on average ~2.5 (see Figure 1.3), and inherent “noise” in gene 
expression can lead to stochastic effects (Elowitz et al., 2002; Chang et al., 2006; To 
and Maheshri, 2010). And third, mRNAs are dynamically processed, with half-
lives sometimes on the order of minutes, and it is unclear how folding in such a 
situation differs from predicted equilibrium folding.  
 The interplay among rates of cleavage, transcription, domain folding, overall 
structural rearrangements, and mRNA processing leading to translation are in the 
end what govern riboswitch function. For example, in the extreme that folding 
and rearrangement rates are much faster than rates of cleavage and mRNA 
processing, it would be predicted that RNA structures would reach their 
thermodynamic equilibrium states quickly. And that ligand addition would allow 
a fully formed MFEF to rearrange into a new ligand-favored fold, modulating 
cleavage activity. This situation is what we refer to when we say “thermodynamic 
switching.” With low energy barriers to structural rearrangement, however, the 
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switches may significantly populate both cleavage-active and cleavage-inactive 
folds in both ligand-present and ligand-absent environments, potentially leading 
to low dynamic ranges. 
 However, with slower rates of structural rearrangements, it may be that 
certain folds that are not thermodynamically favored at equilibrium nevertheless 
dominate, owning to “funneling” effects. Conceptually, a “kinetic” switch might 
function by ligand binding mediating intermediate-energy conformations that 
funnel the switch into ultimately ligand-bound conformations. These ligand-
bound conformations may or may not be thermodynamically favored over the 
ligand-unbound fold, but may dominate owning to high-energy barriers to 
structural rearrangement into the ligand-unbound folds (Figure 2.18).  
Our direct-coupling switches were designed, at least conceptually, to perhaps 
follow this kinetic mechanism. It may be the case that owning to these funneling 
effects, a particular design may lead to a situation where in the presence of ligand, 
a significant majority of mRNAs are permanently funneled into ligand-binding 
conformations, and their corresponding ribozyme states. This may lead to higher 
dynamic ranges compared to thermodynamic switching. In thermodynamic 
switching, low energy barriers among ligand-bound and -unbound states may 
allow for rearrangements and thus ligand-mediated cleavage modulation, but 
perhaps at the expense of high dynamic ranges. With low energy barriers, both 
ligand-bound and -unbound states will be significantly populated at all times.  
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Figure	  2.18	  Conceptual	  energy	  landscape	  of	  ribozyme	  switch	  folding	  	  
Thermodynamic	  and	  kinetic	  considerations,	  along	  with	  rates	  of	  transcription,	  cleavage,	  and	  mRNA	  
processing	  govern	  ribozyme	  switch	  dynamics.	  An	  “ON”-­‐acting	  strand-­‐displacement	  switch	  is	  
“designed”	  to	  function	  thermodynamically,	  wherein	  the	  RNA	  structures	  generally	  exist	  in	  a	  most	  
favorable	  energetic	  fold	  (MFEF).	  Addition	  of	  ligand	  is	  expected	  to	  stabilize	  ligand-­‐binding,	  
ribozyme-­‐inactive	  folds,	  creating	  a	  new	  MFEF	  (green	  arrow).	  Low	  energy	  barriers	  (dashed	  red	  line)	  
allow	  rearrangement	  of	  the	  MFEF	  into	  the	  new	  ligand-­‐binding	  MFEF.	  In	  contrast,	  a	  kinetic	  switch	  is	  
“designed”	  such	  that	  ligand-­‐binding	  before	  reaching	  equilibrium	  “funnels”	  folding	  into	  a	  ligand-­‐
bound	  conformation	  (Near	  “thermodynamic	  neighbor”).	  High-­‐energy	  barriers	  between	  this	  state	  
and	  the	  ligand-­‐unbound	  MFEF	  state	  prevent	  reaching	  the	  equilibrium	  MFEF	  state	  (dashed	  blue	  
line).	  The	  interplay	  among	  relevant	  rates	  of	  structural	  rearrangements,	  mRNA	  translation,	  and	  
ribozyme	  cleavage	  govern	  where	  in	  the	  spectrum	  between	  “thermodynamic”	  and	  “kinetic”	  
switching	  a	  given	  switch	  operates,	  with	  consequences	  in	  dynamic	  ranges.	  	  Switch	  diagrams	  with	  
incomplete	  structure	  represent	  species	  currently	  undergoing	  transcription.	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There is some evidence to suggest that our sd-type switches indeed function 
thermodynamically. For one, our data suggest that sdM switches respond to MS2 
expression both in the nucleus and in the cytoplasm. Because kinetic switches 
would be expected to “funnel” folding states during or shortly after transcription, 
this result suggests that the switching mechanism may be more thermodynamic. 
Second, our in vitro experiments consist of taking fully folded switches and 
exposing them to their ligand in physiological conditions. In these assays, 
presence of ligand is able to modulate cleavage activity, ostensibly through 
structural rearrangement between ligand-bound and unbound states, suggesting 
that these states are indeed accessible from one another. Perhaps also telling, the 
dynamic ranges of our strand-displacement switches do seem to align with 
thermodynamic predictions based on binding affinity, as discussed earlier. While 
not excluding the possibility of developing greater-dynamic range switches, these 
considerations are important to note as possible limitations of the platform.   
Still, the expanded capability of the sd-type ribozyme switch platform to now 
sense protein inputs is further testament to its versatility and input modularity, a 
rare characteristic among eukaryotic gene control platforms. This development 
further expands the potential use of the platform in a variety of situations in 
which altered levels of protein signals are indicative of changes in cellular state. 
With increasing biochemical knowledge of protein-mediated phenotypic changes, 
an ever-expanding set of RNA aptamers (Ellington, 2004), and both rational 
design (Win and Smolke, 2007, 2008b) and directed evolution methods (Liang et 
al., 2012) to generate new ligand-responsive ribozyme switches, our platform is 
poised to allow for greater bespoke cellular reprogramming. 
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2.4 Materials and Methods 
2.4.1 Plasmid and strain construction 
Standard molecular biology techniques were used for DNA manipulation and 
cloning (Sambrook, 2001). Restriction enzymes, T4 DNA ligase, and other cloning 
enzymes were purchased from New England Biolabs (Ipswich, MA). PfuUltraII 
(Agilent Technologies, Santa Clara, CA) was used for high-fidelity PCR 
amplification. LR Clonase II and BP Clonase II (Invitrogen, Carlsbad, CA) were 
used for recombination into Gateway destination plasmids (Addgene, 
Cambridge, MA) following manufacturer’s instructions. Oligonucleotides were 
synthesized by Integrated DNA Technologies (Coralville, IA) or the Stanford 
Protein and Nucleic Acid Facility (Stanford, CA). Plasmids were transformed into 
One Shot Top 10 chemically competent E. coli (Invitrogen, Carlsbad, CA; F-
 mcrA $(mrr-hsdRMS-mcrBC) %80lacZ$M15 $ lacX74 recA1 araD139 
$(araleu)7697 galU galKrpsL (StrR) endA1 nupG) by standard methods. E. coli 
were grown in LB media (BD, Franklin Lakes, NJ) with 100 "g/mL ampicillin 
(EMD Chemicals, Gibbstown, NJ) or 50 µg/mL kanamycin (EMD Chemicals, 
Gibbstown, NJ), depending on the plasmid selection gene. Plasmids were 
prepped from overnight cultures of E. coli using Econospin All-in-One Mini Spin 
Columns (Epoch Biolabs, Missouri City, TX) according to the manufacturers’ 
instructions. Sequencing was performed by Laragen Inc. (Los Angeles, CA) and 
Elim Biopharmaceuticals (Hayward, CA).  
 Plasmids for yeast MS2 or p50 protein expression were based on 
pAG414GPD-ccdB-EGFP (Addgene, Cambridge, MA, Figure 2.20). MS2 was 
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amplified from pCS1592, a gift of James Vowles (Department of Bioengineering, 
Stanford University, Stanford, CA) with primers containing the SV40 large T 
antigen nuclear localization signal, the Protein Kinase Inhibitor nuclear export 
signal, or no tag, immediately downstream of a Kozak sequence and immediately 
upstream of the MS2 or p50 start codon. p50 variants were amplified from pJ593, 
a gift of L. James Maher (Department of Biochemistry and Molecular Biology, 
College of Medicine, Mayo Clinic, Rochester, MN). Cellular localization tags were 
added immediately 5’ of start codons. PCR products were cloned into attL1 and 
attR1 sites within pAG414GPD-ccdB-EGFP (Addgene, Cambridge, MA) using BP 
and LR recombination (Invitrogen, Carlsbad, CA) following manufacturer’s 
instructions.  
Plasmids for characterizing switch activity in yeast were based on pCS1748, 
a centromeric vector encoding an mCherry gene under the control of a TEF1 
promoter, and a yEGFP3 gene under the control of TEF1 promoter (Figure 2.19) 
described previously (Liang et al., 2012). pL203 was constructed by replacing the 
TEF1 promoter upstream yEGFP3 with an ADH1 promoter. ADH1 promoter was 
amplified from plasmid pJZ590d, a gift from Wendell Lim (Department of 
Biochemistry and Biophysics, University of California, San Francisco), and cloned 
at unique ClaI and BamHI sites upstream of yEGFP3 using appropriate restriction 
endonuclease and ligation-mediated cloning. DNA fragments encoding the 
ribozyme-based devices were synthesized as 80nt overlapping oligonucleotides, 
amplified by polymerase chain reaction, and inserted into either pCS1748 or 
pL203 via the unique restriction sites AvrII and XhoI, which are located 3 
nucleotides downstream of the yEGFP3 stop codon.  
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Plasmids for characterization of switch activity in mammalian cells were based 
on pCS2595, a derivative of pcDNA5/FRT (Invitrogen). MS2 was cloned behind a 
modified CMV promoter containing two 3’ tetO binding sites via the unique 
restriction sites NotI and ApaI. tetO sites allow for constitutive suppression of 
MS2 expression in the host HEK 293 T-Rex line (Invitrogen, Carlsbad, CA), which 
can be alleviated by doxycycline induction. Blue fluorescent protein (BFP) was 
cloned downstream of promoter EF1a via unique sites BglII and AvrII containing 
a 5’ Kozak sequence (CGCCCACC). Riboswitch constructs were cloned 
immediately downstream of BFP via the unique restriction sites AvrII and AscI. 
MS2 and BFP sequences used are listed in Figure 2.23. 
2.4.2 Characterization of ribozyme switches in yeast 
Individual plasmids were transformed into yeast strain CSY22, a gal2" mutant 
of W303! (MAT!; leu2-3,112; trp1-1; can1-100; ura3-1; ade2-1; his3-11,15), described 
earlier (Hawkins and Smolke, 2006) using standard lithium-acetate methods 
(Gietz and Woods, 2002). Yeast were grown in YPD or appropriate dropout media 
(BD, Franklin Lakes, NJ) with 2% w/v glucose. Yeast strains were inoculated in 
500 "l appropriate liquid drop out media in 96-well plates and grown in a Lab-
Therm HT-X (Kühner, Basel, Switzerland) at 480 rpm, 30°C, and 80% relative 
humidity overnight. The next day, samples were back-diluted to OD600 ~0.1, 
grown 3–6 hours in the same conditions, and analyzed for fluorescence 
2.4.3 Characterization of ribozyme switches in mammalian cells 
Individual plasmids were transfected into HEK 293 T-Rex line (Invitrogen, 
Carlsbad, CA) using FuGENE HD (Promega, Fitchburg, WI) approximately 24 
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hours after seeding cells on 24-well plates following manufacturer’s instructions. 
Cells were grown in DMEM supplemented with 10% Fetal Bovine Serum (Gibco, 
Carlsbad, CA). Immediately following transfection, 1 mg/L doxycycline was 
added to wells to relieve repression of MS2. Approximately 48 hours after 
transfection, cells were dislodged from adherence to the 24-well plates using 
standard trypsin methods, and analyzed for fluorescence. 
2.4.4 Flow cytometry 
Fluorescence was measured using a MACSQuant VYB (Miltenyi Biotec, 
Cologne, Germany). For GFP characterization, cells were excited with a 488 nm 
laser and signal measured after passing through a 525/50 nm filter. For BFP 
characterization, cells were excited with a 405 nm laser and signal measured after 
passing through a 450/50 nm filter. Viable cells were gated by electronic volume 
and side scatter. Approximately 10,000 cells were analyzed for each culture, and 
the arithmetic mean fluorescence of replicate or triplicate biological samples 
reported. Generally, mean GFP or BFP measurements were normalized by 
dividing by the mean value of a non-cleaving, non-aptamer control ribozyme, Ctl 
(Figure 2.22). 
2.4.5 SPR-based ribozyme binding assays 
SPR experiments were performed on a Biacore X100 (Biacore, Uppsala, 
Sweden) on a CM5 sensor chip (Biacore) modified with a DNA activator strand 
(5&-AAACAACTTTGTTTGTTTCCCCC-/AmMO/) as described previously 
(Kennedy et al., 2012). Full-length RNA was prepared as previously described for 
the cis-blocking strategy without the addition of the radiolabeled nucleotide. The 
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Biacore X100 instrument was equilibrated with the physiologically relevant 
reaction buffer at 37°C unless otherwise specified before all ribozyme binding 
assays. The SPR baseline was stabilized by performing 2–5 startup cycles, where 
each cycle includes a capture and a regeneration step. The capture step was 
performed by an injection of a total of 10–25 ng transcribed cis-blocked RNA 
diluted in HBS EP+ Buffer (Biacore) over the reaction flow cell (FC2) for 1 min at a 
flow rate of 10 "l/min. The capture step typically yielded ∼50–300 RU of the SPR 
signal for the described constructs. The regeneration step was performed by an 
injection of 25 mM NaOH over both flow cells for 30 sec at a flow rate of 30 
"l/min. 
Following the startup cycles, assay cycles were performed. Each assay cycle 
includes a capture, a reaction and a regeneration step. The capture and 
regeneration steps in an assay cycle were performed as described for those in the 
startup cycle. The reaction step was performed by an injection of the running 
buffer containing 500 "M MgCl2 over both FCs for 5 min at a flow rate of 10 
"l/min. When noted, appropriate concentrations of purified mBP-MS2 (gift of 
Rachel Green, Department of Chemical Engineering, Johns Hopkins University),  
were added to FC1. Biacore sensorgram processing and analysis were performed 
using Biacore X100 Evaluation Software v2.0 (Biacore). The processed sensorgram 
(R) was fit to a simple exponential equation R = (R0 – R∞) × (e−kdt) + R∞, where 
R0 (fit globally for a given replicate) is the initial SPR signal before the cleavage 
reaction, R∞ (fit locally for a given replicate) is the residual response at the end of 
the cleavage reaction and kd is the first-order RNA dissociation rate constant.  
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2.4.6 Gel-based ribozyme cleavage assays 
Generation of radiolabeled, full-length MS2-responsive RNA devices was 
carried out as previously described for natural hammerhead ribozymes and 
theophylline-responsive RNA devices (Kennedy et al., 2012). Cleavage assays to 
determine cleavage kinetics were also adapted from the previous work. Briefly, 
gel-based ribozyme cleavage assays were performed in a physiologically relevant 
reaction buffer (40 "l) composed of 500 "M MgCl2, 150 mM NaCl, 1 mM DTT and 
10 mM HEPES (pH 7.4) at 37°C. In the reaction volume, 200–400 nM of 
radiolabeled, full-length RNA generated from the cis-blocking strategy was first 
incubated with 2.5 "M DNA activator strand (5&-
AAACAACTTTGTTTGTTTCCCCC), for 2 min to activate the blocked RNA and 
specified amount of mBP-MS2 protein (Courtesy Rachel Green, Department of 
Chemical Engineering, Johns Hopkins University). The zero time-point aliquot 
was taken before initiating the self-cleavage reaction with the addition of MgCl2. 
Reactions were quenched at specified time points with addition of 3 volumes of 
RNA stop/load buffer (95% formamide, 30 mM EDTA, 0.25% bromophenol blue, 
0.25% xylene cyanol) on ice. Samples were size-fractionated on a denaturing (8.3 
M Urea) 8% polyacrylamide gel at 55 W for 35–45 min. Gels were exposed 
overnight on a phosphor screen and imaged on a FX Molecular Imager (Bio-Rad, 
Hercules, CA). The relative levels of the full-length transcript and cleaved 
products were determined by phosphorimaging analysis. To determine k, the 
first-order rate constant of self-cleavage, the cleaved product fraction at each time 
point (Ft) was fit to the single exponential equation Ft = F0 + (F∞ − F0) × (1 – e−kt) 
using Prism 5 (GraphPad, La Jolla, CA), where F0 and F∞ are the fractions cleaved 
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before the start of the reaction and at the reaction endpoint, respectively. All 
reported cleavage rate constants are the mean of at least three independent 
experiments. 
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Supplementary Information 
1993 SacI (1)
1668 NaeI (1)
1668 NgoMIV (1)
F1 ori 1781..1475
1234 NsiI (1)
46 PfoI (1)
TEF1p 1999..2402
2403 SacII (1)
2544 EcoNI (1)
2870 BseRI (1)
CYC1t 3143..3404
3405 XbaI (1)
3806 BbeI (1)
3806 KasI (1)
3806 NarI (1)
3806 SfoI (1)
3961 ClaI (1)
5395 Acc65I (1)
5395 KpnI (1)
ADH1t 5155..5394
5158 BssHII (1)
5157 AscI (1)
5149 XhoI (1)
5142 AvrII (1)
5112 PflMI (1)
4982 MfeI (1)
4909 HpaI (1)
yEGFP 4423..5139
4407 BglII (1)
4399 HindIII (1)
4387 EcoRI (1)
4375 SmaI (1)
4375 XmaI (1)
4369 BamHI (1)
TEF1p 3965..4368
6681 Eam1105I (1)
AmpR 7275..6616
7617 PmlI (1)
7640 SwaI (1)
CEN6_ARSH4 7605..8123
pCS1748
8187 bp
388 SbfI (1)
URA3 411..1211
ymCherry 2409..3134
3135 NotI (1)
3137 SfiI (1)
3325 MluI (1)
3687 Tth111I (1)
532 XcmI (1)
Figure	  2.19	  Plasmid	  pCS1748	  used	  for	  device	  characterization	  in	  yeast	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541 SwaI (1)
3460 SpeI (1)
attR1 3478..3602
attR2 3602..3502
3603 NotI (1)
3920 AccIII (1)
5937 XhoI (1)
5232 BseRI (1)
4796 SmaI (1)
4796 XmaI (1)
4795 SrfI (1)
4225 NcoI (1)
4225 StyI (1)
6115 MluI (1)
6195 Acc65I (1)
6195 KpnI (1)
6523 NaeI (1)
6523 NgoMIV (1)
6626 DraIII (1)
7380 Bsu36I (1)
7544 BstAPI (1)
pAG414GPD-ccdB-EGFP
8093 bp
1497 Eam1105I (1)
AmpR 715..1575
TRP1 7626..6952
CYC1t 5950..6189
Y66 (EGFP) 5400..5429
EGFP 5220..5933
attR2 5061..5161
ccdB 4715..5020
CAT/CamR 3711..4370
lacp 3627..3650
2788 SacI (1)
2390 BspLU11I (1)
pBR322 ori 1730..2349
CEN6_ARSH4 583..65
4830 BtrI (1)
5055 SalI (1)
attR1 5168..5061
Figure	  2.20	  Plasmid	  used	  for	  MS2	  and	  p50	  expression	  in	  yeast	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1588 SpeI (2)
1567 MluI (1)
1558 SmaI (1)
1558 XmaI (1)
bGHpA 1314..1539
1282 BssHII (1)
1281 AscI (1)
1272 AvrII (1)
1272 StyI (5)
Last amino acid 1266..1268
1209 DraIII (3)
991 StuI (1)
pTagBFP 589..1268
BFP 570..1271
822 Bsu36I (2)
607 BsrGI (1)
Kozak sequence 563..573
553 XhoI (2)
459 NaeI (3)
459 NgoMIV (3)
437 StyI (5)
309 Bsu36I (2)
EF1a 18..552
107 AgeI (1)
100 MfeI (1)
12 BglII (1)
CMV TetO2 1571..2208
1927 SnaBI (1)
1949 NcoI (2)
1949 StyI (5)
2153 SacI (3)
2201 SalI (4)
2209 Acc65I (1)
2209 KpnI (1)
2215 SacI (3)
2221 BamHI (1)
2227 SpeI (2)
2254 EcoRV (1)
2270 NotI (1)
2277 XhoI (2)
2316 SalI (4)
2337 BtrI (1)
2438 SacI (3)
MS2 2283..2678
2495 XcmI (1)
2683 ApaI (1)
2683 Bsp120I (1)
bGHpA 2714..2938
3109 NaeI (3)
3109 NgoMIV (3)
FRT 3222..3269
3249 XbaI (1)
3269 StyI (5)
4940 BspLU11I (1)
4566 SalI (4)
4559 BstZ17I (1)
SV40 4429..4559
4446 PsiI (1)
4372 NaeI (3)
4372 NgoMIV (3)
4051 SacII (1)
4032 AccIII (2)
3850 DraIII (3)
3849 BstAPI (2)
HygroR 3277..4297
3681 RsrII (1)
3626 NcoI (2)
3626 StyI (5)
3573 BstAPI (2)
3557 DraIII (3)
3495 AccIII (2)
pUC 5615..4942
5828 Eam1105I (1)
Ampicillin 6620..5760
6428 XmnI (1)
6635 SspI (1)
Bla 6719..6621
6754 SalI (4)
pCS2595
6756 bp
Figure	  2.21	  Plasmid	  use	  for	  device	  characterization	  in	  mammalian	  cells	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Figure	  2.22	  Ribozyme	  switch	  sequences	  used	  in	  the	  study	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Ctl Ctl pCS1751 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTACGTGAGGTCCGT
GAGGACAGAACAGCAAAAAGAAAAATAAAAA 
RSV RSV pCS1750 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
GAGGACGAAACAGCAAAAAGAAAAATAAAAA 
sdM1 D1 pL401 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
TGTCCAGGATCACCGGACGGGACGGAGGACGAAACAGCAAAAAGAAAAA
TAAAAA 
sdM2 D2 pL402 AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGT
TGTCCACCATCAGGGGACGGGACGGAGGACGAAACAGCAAAAAGAAAAA
TAAAAA 
sdM3 D3 pL403 AAACAAACAAAGCTGTCACCGGATGTGCTGCAGGATCACCGCATTTCCG
GTCTGATGAGTCCGTGAGGACGAAACAGCAAAAAGAAAAATAAAAA 
sdM4 D7 pL404 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
GGTCCACCATCAGGGGACTGGACTGAGGACGAAACAGCAAAAAGAAAAA
TAAAAA 
dc1M1 dc1M1 pL254 AAACAAACAAAGCTGTCACCGGATGTGCATGAGGATTACCCATTTTCCG
GTCTGATGAGTCCGTGAGGACGAAACAGCAAAAAGAAAAATAAAAA 
dc1M2 dc1M2 pL259 AAACAAACAAAGCTGTCACCGGATGTGCATGAGGATCACCCATTTTCCG
GTCTGATGAGTCCGTGAGGACGAAACAGCAAAAAGAAAAATAAAAA 
dc1M3 dc1M3 pL255 AAACAAACAAAGCTGTCACCGGATGTGCCCCAGGATCACCGGGTTTCCG
GTCTGATGAGTCCGTGAGGACGAAACAGCAAAAAGAAAAATAAAAA 
dc3M1 dc3M1 pL256 AAACAAACAAAATGAGGATGCTGTCACCGGATGTGCTTTCCGGTCTGAT
GAGTCCGTGAGGACGAAACAGCCACCCATAAAAAGAAAAATAAAAA 
dc3M2 dc3M2 pL257 AAACAAACAAAATGAGGATGCTGTCACCGGATGTGCTTTCCGGTCTGAT
GAGTCCGTGAGGACGAAACAGCCACCCATAAAAAGAAAAATAAAAA 
dc3M3 dc3M3 pL258 AAACAAACAAACCCAGGATGCTGTCACCGGATGTGCTTTCCGGTCTGAT
GAGTCCGTGAGGACGAAACAGCCACCGGGAAAAAGAAAAATAAAAA 
dc1K1 dc1K1 pL220 AAACAAACAAAGCTGTCACCGGATGTGCGGATCCTGAAACTGTTTTAAG
GTTGGCCGATCCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAA
AAAGAAAAATAAAAA 
dc3K1 dc3K1 pL222 AAACAAACAAAGGATCCTGAAACTGTTTCTGTCACCGGATGTGCTTTCC
GGTCTGATGAGTCCGTGAGGACGAAACAGTAAGGTTGGCCGATCCAAAA
AGAAAAATAAAAA 
dc1K2 Kb45 pL250 AAACAAACAAAGCTGTCACCGGAGGATCCTGAAACTGTTTTAAGGTTGG
CCGATCCTGTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAA
AAAGAAAAATAAAAA 
dc1K3 Kb55 pL251 AAACAAACAAAGCTGTCACCGGATGGATCCTGAAACTGTTTTAAGGTTG
GCCGATCCGTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAA
AAAGAAAAATAAAAA 
dc1K4 Kb65 pL252 AAACAAACAAAGCTGTCACCGGATGGGATCCTGAAACTGTTTTAAGGTT
GGCCGATCCTGCTTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAA
AAAGAAAAATAAAAA 
dc1K5 Kb75 pL253 AAACAAACAAAGCTGTCACCGGATGTGCTGGATCCTGAAACTGTTTTAA
GGTTGGCCGATCCTTCCGGTCTGATGAGTCCGTGAGGACGAAACAGCAA
AAAGAAAAATAAAAA 
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Figure	  2.23	  Genetic	  element	  sequences	  used	  in	  the	  study	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NES TTGGCTTTGAAATTGGCTGGTTTGGATATT
NLS CCAAAAAAGAAGAGAAAGGTC
KZ TAAAAAAAATG
P50 pL195 ATGGCAGAAGATGATCCATATTTGGGAAGGCCTGAACAAATGTTTCATTTGGA
TCCTTCTTTGACTCATACAATATTTAATCCAGAAGTATTTCAACCACAGATGG
CACTGCCAACAGATGGCCCATACCTTCAAATATTAGAGCAACCTAAACAGAGA
GGATTTCGTTTCCGTTATGTATGTGAAGGCCCATCCCATGGTGGACTACCTGG
TGCCTCTAGTGAAAAGAACAAGAAGTCTTACCCTCAGGTCAAAATCTGCAACT
ATGTGGGACCAGCAAAGGTTATTGTTCAGTTGGTCACAAATGGAAAAAATATC
CACCTGCATGCCCACAGCCTGGTGGGAAAACACTGTGAGGATGGGATCTGCAC
TGTAACTGCTGGACCCAAGGACATGGTGGTCGGCTTCGCAAACCTGGGTATAC
TTCATGTGACAAAGAAAAAAGTATTTGAAACACTGGAAGCACGAATGACAGAG
GCGTGTATAAGGGGCTATAATCCTGGACTCTTGGTGCACCCTGACCTTGCCTA
TTTGCAAGCAGAAGGTGGAGGGGACCGGCAGCTGGGAGATCGGGAAAAAGAGC
TAATCCGCCAAGCAGCTCTGCAGCAGACCAAGGAGATGGACCTCAGCGTGGTG
CGGCTCATGTTTACAGCTTTTCTTCCGGATAGCACTGGCAGCTTCACAAGGCG
CCTGGAACCCGTGGTATCAGACGCCATCTATGACAGTAAAGCCCCCAATGCAT
CCAACTTGAAAATTGTAAGAATGGACAGGACAGCTGGATGTGTGACTGGAGGG
GAGGAAATTTATCTTCTTTGTGACAAAGTTCAGAAAGATGACATCCAGATTCG
ATTTTATGAAGAGGAAGAAAATGGTGGAGTCTGGGAAGGATTTGGAGATTTTT
CCCCCACAGATGTTCATAGACAATTTGCCATTGTCTTCAAAACTCCAAAGTAT
AAAGATATTAATATTACAAAACCAGCCTCTGTGTTTGTCCAGCTTCGGAGGAA
ATCTGACTTGGAAACTAGTGAACCAAAACCTTTCCTCTACTATCCTGAAATCA
AAGATAAAGAAGAAGTGCAGAGGAAACGTCAGAAGCTCATGCCCAATTTTTCG
GATAGTTTCGGCGGTGGTAGTGGTGCCGGAGCTGGAGGCGGAGGCATGTTTGG
TAGTGGCGGTGGAGGAGGGGGCACTGGAAGTACAGGTCCAGGGTATAGCTTCC
CACACTATGGATTTCCTACTTATGGTGGGATTACTTTCCATCCTGGAACTACT
AAATCTAATGCTGGGATGAAGCATGGAACCATGGACACTGAATCTAAAAAGGA
CCCTGAAGGTTGTGACAAAAGTGATGACAAAAACACTGTAAACCTCTTTGGGA
AAGTTATTTGA 
MS2 pCS1592 ATGGCTTCTAACTTTACTCAGTTCGTTCTCGTCGACAATGGCGGAACTGGCGA
CGTGACTGTCGCCCCAAGCAACTTCGCTAACGGGGTCGCTGAATGGATCAGCT
CTAACTCGCGTTCACAGGCTTACAAAGTAACCTGTAGCGTTCGTCAGAGCTCT
GCGCAGAATCGCAAATACACCATCAAAGTCGAGGTGCCTAAAGTGGCAACCCA
GACTGTTGGTGGTGTAGAGCTTCCTGTAGCCGCATGGCGTTCGTACTTAAATA
TGGAACTAACCATTCCAATTTTCGCCACGAATTCCGACTGCGAGCTTATTGTT
AAGGCAATGCAAGGTCTCCTAAAAGATGGAAACCCGATTCCCTCGGCCATCGC
GGCAAACTCCGGCATCTACTAG 
ADH1p pL203 TAAAACAAGAAGAGGGTTGACTACATCACGATGAGGGGGATCGAAGAAATGAT
GGTAAATGAAATAGGAAATCAAGGAGCATGAAGGCAAAAGACAAATATAAGGG
TCGAACGAAAAATAAAGTGAAAAGTGTTGATATGATGTATTTGGCTTTGCGGC
GCCGAAAAAACGAGTTTACGCAATTGCACAATCATGCTGACTCTGTGGCGGAC
CCGCGCTCTTGCCGGCCCGGCGATAACGCTGGGCGTGAGGCTGTGCCCGGCGG
AGTTTTTTGCGCCTGCATTTTCCAAGGTTTACCCTGCGCTAAGGGGCGAGATT
GGAGAAGCAATAAGAATGCCGGTTGGGGTTGCGATGATGACGACCACGACAAC
TGGTGTCATTATTTAAGTTGCCGAAAGAACCTGAGTGCATTTGCAACATGAGT
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ATACTAGAAGAATGAGCCAAGACTTGCGAGACGCGAGTTTGCCGGTGGTGCGA
ACAATAGAGCGACCATGACCTTGAAGGTGAGACGCGCATAACCGCTAGAGTAC
TTTGAAGAGGAAACAGCAATAGGGTTGCTACCAGTATAAATAGACAGGTACAT
ACAACACTGGAAATGGTTGTCTGTTTGAGTACGCTTTCAATTCATTTGGGTGT
GCACTTTATTATGTTACAATATGGAAGGGAACTTTACACTTCTCCTATGCACA
TATATTAATTAAAGTCCAATGCTAGTAGAGAAGGGGGGTAACACCCCTCCGCG
CTCTTTTCCGATTTTTTTCTAAACCGTGGAATATTTCGGATATCCTTTTGTTG
TTTCCGGGTGTACAATATGGACTTCCTCTTTTCTGGCAACCAAACCCATACAT
CGGGATTCCTATAATACCTTCGTTGGTCTCCCTAACATGTAGGTGGCGGAGGG
GAGATATACAATAGAACAGATACCAGACAAGACATAATGGGCTAAACAAGACT
ACACCAATTACACTGCCTCATTGATGGTGGTACATAACGAACTAATACTGTAG
CCCTAGACTTGATAGCCATCATCATATCGAAGTTTCACTACCCTTTTTCCATT
TGCCATCTATTGAAGTAATAATAGGCGCATGCAACTTCTTTTCTTTTTTTTTC
TTTTCTCTCTCCCCCGTTGTTGTCTCACCATATCCGCAATGACAAAAAAATGA
TGGAAGACACTAAAGGAAAAAATTAACGACAAAGACAGCACCAACAGATGTCG
TTGTTCCAGAGCTGATGAGGGGTATCTCGAAGCACACGAAACTTTTTCCTTCC
TTCATTCACGCACACTACTCTCTAATGAGCAACGGTATACGGCCTTCCTTCCA
GTTACTTGAATTTGAAATAAAAAAAAGTTTGCTGTCTTGCTATCAAGTATAAA
TAGACCTGCAATTATTAATCTTTTGTTTCCTCGTCATTGTTCTCGTTCCCTTT
CTTCCTTGTTTCTTTTTCTGCACAATATTTCAAGCTATACCAAGCATACAATC
AACTATCTCATATACA  
yEGFP3 pCS321 ATGTCGAAAGCTACATATAAGGAACGTGCTGCTACTCATCCTAGTCCTGTTGC
TGCCAAGCTATTTAATATCATGCACGAAAAGCAAACAAACTTGTGTGCTTCAT
TGGATGTTCGTACCACCAAGGAATTACTGGAGTTAGTTGAAGCATTAGGTCCC
AAAATTTGTTTACTAAAAACACATGTGGATATCTTGACTGATTTTTCCATGGA
GGGCACAGTTAAGCCGCTAAAGGCATTATCCGCCAAGTACAATTTTTTACTCT
TCGAAGACAGAAAATTTGCTGACATTGGTAATACAGTCAAATTGCAGTACTCT
GCGGGTGTATACAGAATAGCAGAATGGGCAGACATTACGAATGCACACGGTGT
GGTGGGCCCAGGTATTGTTAGCGGTTTGAAGCAGGCGGCAGAAGAAGTAACAA
AGGAACCTAGAGGCCTTTTGATGTTAGCAGAATTGTCATGCAAGGGCTCCCTA
TCTACTGGAGAATATACTAAGGGTACTGTTGACATTGCGAAGAGCGACAAAGA
TTTTGTTATCGGCTTTATTGCTCAAAGAGACATGGGTGGAAGAGATGAAGGTT
ACGATTGGTTGATTATGACACCCGGTGTGGGTTTAGATGACAAGGGAGACGCA
TTGGGTCAACAGTATAGAACCGTGGATGATGTGGTCTCTACAGGATCTGACAT
TATTATTGTTGGAAGAGGACTATTTGCAAAGGGAAGGGATGCTAAGGTAGAGG
GTGAACGTTACAGAAAAGCAGGCTGGGAAGCATATTTGAGAAGATGCGGCCAG
CAAAACTAA 
mBFP pCS2595 ATGAGCGAGCTGATTAAGGAGAACATGCACATGAAGCTGTACATGGAGGGCAC
CGTGGACAACCATCACTTCAAGTGCACATCCGAGGGCGAAGGCAAGCCCTACG
AGGGCACCCAGACCATGAGAATCAAGGTGGTCGAGGGCGGCCCTCTCCCCTTC
GCCTTCGACATCCTGGCTACTAGCTTCCTCTACGGCAGCAAGACCTTCATCAA
CCACACCCAGGGCATCCCCGACTTCTTCAAGCAGTCCTTCCCTGAGGGCTTCA
CATGGGAGAGAGTCACCACATACGAAGACGGGGGCGTGCTGACCGCTACCCAG
GACACCAGCCTCCAGGACGGCTGCCTCATCTACAACGTCAAGATCAGAGGGGT
GAACTTCACATCCAACGGCCCTGTGATGCAGAAGAAAACACTCGGCTGGGAGG
CCTTCACCGAGACGCTGTACCCCGCTGACGGCGGCCTGGAAGGCAGAAACGAC
ATGGCCCTGAAGCTCGTGGGCGGGAGCCATCTGATCGCAAACATCAAGACCAC
ATATAGATCCAAGAAACCCGCTAAGAACCTCAAGATGCCTGGCGTCTACTATG
TGGACTACAGACTGGAAAGAATCAAGGAGGCCAACAACGAGACCTACGTCGAG
CAGCACGAGGTGGCAGTGGCCAGATACTGCGACCTCCCTAGCAAACTGGGGCA
CAAGCTTAATTGA 
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Chapter 3 
Development of a modular genetic amplifier for 
near-digital control over eukaryotic gene 
expression 
Abstract	  
In	  synthetic	  biology,	  engineered	  gene	  regulation	  is	  often	  achieved	  using	  synthetic	  transcription	  
factors	  (TFs).	  Although	  allowing	  for	  high-­‐fold	  changes	  in	  output	  gene	  expression	  in	  response	  to	  
various	  inputs,	  it	  is	  generally	  exceedingly	  difficult	  to	  generate	  TFs	  that	  respond	  to	  a	  new	  input	  of	  
interest.	  RNA-­‐based	  gene	  control,	  on	  the	  other	  extreme,	  has	  proved	  versatile	  and	  modular,	  although	  
generally	  regulatory	  dynamic	  ranges	  of	  output	  gene	  expression	  have	  been	  modest.	  The	  limitations	  of	  
both	  kinds	  of	  regulation	  hamper	  efforts	  in	  developing	  more	  sophisticated	  synthetic	  biological	  
systems.	  Here	  we	  develop	  a	  modular	  genetic	  amplifier	  for	  near-digital	  control	  over	  eukaryotic	  gene	  
expression.	  We	  combine	  ribozyme	  switch-­‐mediated	  regulation	  of	  a	  synthetic	  TF	  with	  TF-­‐mediated	  
regulation	  of	  an	  output	  gene.	  The	  amplifier	  platform	  allows	  for	  as	  much	  as	  20-­‐fold	  regulation	  of	  
output	  gene	  expression	  in	  response	  to	  input	  signal,	  with	  maximal	  expression	  approaching	  the	  highest	  
levels	  observed	  in	  yeast,	  yet	  tunable	  to	  intermediate	  and	  lower	  levels.	  EC50	  values	  are	  more	  than	  4	  
times	  lower	  than	  in	  previously	  best-performing,	  non-amplifier	  ribozyme	  switches.	  The	  system	  design	  
retains	  the	  modular-input	  architecture	  of	  the	  ribozyme	  switch	  platform,	  and	  the	  near-digital	  
dynamic	  ranges	  of	  TF-based	  gene	  control.	  This	  combination	  of	  characteristics	  suggest	  great	  potential	  
for	  the	  wide	  applicability	  of	  this	  amplifier	  platform	  for	  more	  sophisticated,	  customizable	  regulation	  
of	  cellular	  activity.	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3.1 Introduction 
Cells have evolved to survive and make efficient use of often scant and 
changing resources by tailoring gene expression to environmental conditions. 
Gene control circuits must often convey input signals—usually changing levels 
of relevant molecules—into homogeneous phenotypic outputs—usually by 
altering expression of phenotype-setting genes. This must be achieved even 
when circuit component levels can be “noisy” due to inherent properties of 
biological processes (Elowitz et al., 2002; Munsky et al., 2012). A commonly 
evolved strategy has been to institute near-digital control over expression of 
phenotype-setting genes by amplification. In this manner, an input signal causes 
an output gene to be unambiguously turned “ON” or “OFF,” allowing a 
biological system architecture to elicit homogenous changes in phenotype in a 
population of cells even when input signal and cell-to-cell variability may be 
significant. For example, whereas yeast preferentially consume glucose as a food 
source, in conditions of glucose depravation and galactose abundance, complex 
circuits containing various feedback loops allow for high-fold changes in 
expression of galactose metabolism genes (Ramsey et al., 2006; Sellick et al., 
2008). This amplified high-fold, or “digital,” regulation of galactose metabolism 
genes allows the organism to thrive in the presence of galactose, while not 
 83 
wasting resources synthesizing unneeded genes when preferred glucose is 
abundant.  
For many components of the galactose system, as with many other natural 
gene circuits, this digital control over output gene expression is achieved by 
feedback loops, wherein a transcription factor (TF) can activate (or repress) both 
the output gene and itself. This allows a small input-mediated change in TF 
activity to self-amplify for maximal output gene modulation. Examples of both 
positive and negative feedback amplification abound in natural systems 
(Bateman, 1998).  
Another phenomenon that can allow for amplification, and digital control 
over gene output, is cooperativity, wherein a small change in effector protein 
activity amplifies not the level of the effector itself, but further changes in effector 
activity. For example, the E. coli Tn10 tetracycline repressor (tetR) is a 
homodimer protein that can tightly bind tetracycline operator (tetO) DNA sites, 
and block transcription of neighboring genes. Tetracycline binding to tetR 
mediates cooperative regulation of tetR–tetO binding activity (Reichheld et al., 
2009). tetR family proteins have been shown to display cooperative binding to 
adjacent operator sites by modulating conversion of neighboring target operators 
from B-form DNA to the under-twisted form that facilitates further tetR binding 
(Ramos et al., 2005). It is interesting to note that TFs, whose evolved function is 
often to convey an input signal into a digital response, in many examples consist 
of multimeric proteins that bind repetitive target sequences, e.g., Lambda 
repressor cI, tetR, Nuclear Factor-!B, and many other classic examples. Further, 
there are many examples of cooperative binding between different transcription 
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factors (Banerjee, 2003; Chang et al., 2006). Nature, it may be argued, has found 
cooperativity a useful tool for achieving digital control over gene expression.  
As synthetic biology continues to mature and promise solutions to many 
pressing needs, burgeoning potential applications necessitate more digital 
control over output gene expression. For some applications, this has already been 
successfully demonstrated. Synthetic TFs, for example, have been widely used in 
synthetic biology applications to date to achieve digital control over target gene 
expression. In one such example, tetR was fused to the activation domain of the 
herpes simplex virus protein 16 (VP16) to generate a tetracycline trans activator 
(tTA) (Gossen and Bujard, 1992). Binding of the tetR domain to tetO sites placed 
adjacent to a minimal promoter drove expression of a downstream target gene in 
response to expression of tTA. Addition of tetracycline, which modulates the 
conformation and activity of tTA, lowered gene expression by up to five orders 
of magnitude. Similar systems that respond differently to tetracycline, or to 
several other ligands, have also been developed or adopted from natural 
architectures. In yeast, one group has developed modular binding domains 
composed of zinc-finger proteins that allow for orthogonal regulation of different 
target genes by different TF variants with various regulatory dynamics, while 
still retaining large dynamic ranges on the order of ~100 fold (Khalil et al., 2012). 
Synthetic TF-mediated gene control has been applied to metabolic pathways in E. 
coli, sensing levels of key intermediates and accordingly regulating enzyme 
expression, greatly increasing end product yields (Farmer and Liao, 2000; Zhang 
et al., 2012). This suggests that employing this strategy in other pathways may 
similarly result in better system performance. Synthetic TFs have also been 
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constructed with feedback architectures, leading to gene regulation at impressive 
dynamic ranges (Nistala et al., 2010). Other TF-based strategies, such as TF-
regulated integrases, have allowed for the construction of complex biological 
circuits with greatly amplified digital outputs (Bonnet et al., 2013).  
Impressive as they are, these efforts largely make use of TF elements that 
respond to specific inputs, and except for rare examples that modify an existing 
TF sensor element to respond to an input molecule very similar to the original 
(Collins et al., 2005), it remains very difficult to engineer a TF to respond to a 
novel input. Another approach to gene regulation has been to use synthetic RNA 
(Liang et al., 2011). These platforms enjoy potentially greater input modularity 
owing to the wide availability of RNA sequences that sense various molecules of 
interest and established methods to develop new sensors (Ellington and Szostak, 
1990; Tuerk and Gold, 1990; Ellington, 2004), combined with relative accuracy of 
RNA structure-function prediction (Mathews et al., 1999; Zuker, 2003; Reuter and 
Mathews, 2010), 
One such platform is the ribozyme switch (Win and Smolke, 2008b), in which 
small-molecule aptamers integrated into a self-cleaving hammerhead ribozyme 
placed in the 3’ untranslated region (UTR) of a transgene can allow for allosteric 
regulation of transgene expression in both yeast and mammalian cells (Win and 
Smolke, 2007, 2008b; Chen et al., 2010; Wei et al., 2013). The platform has been 
further developed for complex logical computation (Win and Smolke, 2008a) and 
high-throughput in vivo tuning and in vitro characterization (Kennedy et al., 2012; 
Liang et al., 2012). Because of its modular construction, it can be used to regulate 
any transgene, and to respond to any input to which a suitable aptamer can be 
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developed, including small molecules (Win and Smolke, 2008a, 2008b) and 
proteins (d’Espaux et al., 2013). Unfortunately, as with RNA-based gene control 
systems in general, dynamic ranges have so far been modest compared to TF-
based control, with a maximum of ~10-fold gene expression modulation even 
after engineered tuning and directed evolution (Liang et al., 2012).  For many 
applications, however, the importance of the modular-input architecture of 
RNA-based gene control cannot be overstated. It thus has remained an important 
goal in the field to develop ways of amplifying riboswitch-mediated gene 
control, empowering applications that necessitate sensing novel inputs.  
Here we report the development of modular genetic amplifier platform for 
near-digital control over gene expression in eukaryotic cells. The amplifier 
platform combines a synthetic TF with ribozyme switch-mediated allosteric 
regulation. It exhibits high-dynamic range modulation of output gene 
expression, up to 20 fold, stemming from cooperative activity of the TF 
component. The platform’s output is amplified over output from a ribozyme 
switch-only platform, allowing for lower input EC50 values and maximal output 
gene expression in the “ON” state. The amplifier retains the modular-input 
architecture of the ribozyme switch platform. Further, availability of TF 
components that can activate or repress with various regulatory dynamics 
(Witzgall et al., 1994; Lamartina, 2003), and that can bind orthogonal modular 
output operator sequences with digital responses (Khalil et al., 2012) suggest that 
the amplifier may generally be employed to sense varied and novel modular 
inputs to control modular outputs, with various and often digital regulatory 
profiles. 
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Figure	  3.1	  Design	  of	  ribozyme	  switch	  platform	  
A	  hammerhead	  ribozyme	  is	  a	  naturally	  occurring	  RNA	  sequence	  that	  can	  undergo	  rapid,	  site-­‐
specific	  self-­‐cleavage	  (site	  indicated	  by	  red	  scissors).	  A	  synthetic	  ribozyme	  switch	  couples	  this	  
ribozyme	  to	  a	  ligand-­‐binding	  aptamer	  sequence	  (black	  bases)	  through	  engineered	  transmitter	  
sequences	  (pink	  bases).	  The	  switch	  is	  encoded	  in	  the	  3’	  untranslated	  region	  of	  a	  target	  gene,	  in	  
this	  case	  GFP,	  and	  upon	  transcription	  in	  eukaryotic	  cells	  is	  designed	  to	  exist	  in	  two	  primary	  
conformations.	  In	  this	  example	  of	  an	  “ON”	  switch,	  conformations	  are	  mutually	  exclusive	  in	  
whether	  they	  contain	  a	  ribozyme-active	  domain	  or	  an	  aptamer-folded	  domain.	  Ribozyme-­‐
active	  conformations	  undergo	  cleavage,	  leading	  to	  rapid	  exonuclease-mediated	  transcript	  
degradation,	  and	  loss	  of	  GFP	  expression.	  Binding	  of	  a	  ligand	  (yellow	  circle)	  stabilizes	  the	  
aptamer-folded	  conformation,	  which	  in	  this	  case	  is	  diminishes	  cleavage	  activity,	  and	  allows	  for	  
greater	  GFP	  expression.	  Thus,	  increased	  levels	  of	  ligand	  lead	  to	  target	  gene	  expression	  being	  
turned	  “ON.”	  In	  “OFF”	  switch	  designs	  (not	  shown),	  ribozyme-active	  and	  aptamer-folded	  
domains	  are	  mutually	  inclusive.	  In	  the	  absence	  of	  ligand,	  transcripts	  primarily	  do	  not	  undergo	  
cleavage,	  but	  do	  so	  when	  ligand	  binding	  stabilizes	  the	  aptamer-folded	  and	  ribozyme-active	  
conformation.	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3.2 Results and Discussion 
3.2.1 Design of a modular genetic amplifier 
We developed a genetic amplifier platform composed of two genetic 
cassettes: a synthetic transcription factor (TF) whose levels are regulated by a 
ribozyme switch, and a target gene whose levels are regulated by a TF-
responsive promoter. For our TF, we chose the well-characterized tetracycline 
trans activator (tTA), which consists of the E. coli tetracycline repressor (tetR) 
fused to the activation domain of the herpes simplex virus protein 16 (VP16) 
(Gossen and Bujard, 1992). We placed a ligand-responsive riboswitch in the 3’ 
UTR of the tTA gene to allow for ribozyme switch-mediated modulation of tTA 
expression in response to ligand levels. For our target, we cloned a reporter GFP 
gene under the control of tTA-inducible synthetic promoters, which consist of 
tetracycline operator (tetO) sequences adjacent to a minimal promoter containing 
a “TATA” box and a leader sequence from the yeast CYC1 promoter. The 
minimal promoter does not yield appreciable GFP expression alone. However, 
binding of tTA at tetO sites mediate recruitment of other TFs to induce 
expression of the target downstream gene (Garí et al., 1997) (Figure 3.2).  
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Figure	  3.2	  Design	  of	  modular	  genetic	  amplifier	  platform	  
The	  amplifier	  platform	  consists	  of	  the	  ribozyme	  switch	  platform	  layered	  with	  transcription	  factor	  
(TF)-­‐mediated	  regulation	  of	  the	  output	  gene.	  Ribozyme	  switch-­‐mediated,	  ligand-­‐dependent	  
regulation	  occurs	  as	  in	  the	  normal	  ribozyme	  switch	  architecture,	  but	  in	  the	  amplifier	  platform	  is	  
employed	  to	  regulate	  expression	  of	  TF	  tTA.	  In	  this	  “ON”	  switch	  design,	  increased	  levels	  of	  ligand	  
modulate	  ribozyme	  cleavage	  activity	  to	  increase	  levels	  of	  tTA.	  The	  amplifier	  architecture	  adds	  
another	  layer	  of	  regulation,	  in	  that	  tTA	  regulates	  expression	  of	  a	  reporter	  GFP	  gene	  by	  
transcriptional	  control.	  The	  tTA	  synthetic	  TF	  is	  composed	  of	  a	  transcriptional	  activator	  VP16	  
domain	  (AD)	  fused	  to	  a	  tetR	  DNA	  binding	  domain	  (BD).	  In	  the	  absence	  of	  tTA,	  the	  tetO	  promoter	  	  
does	  not	  allow	  for	  appreciable	  GFP	  expression.	  Increased	  levels	  of	  tTA	  lead	  to	  BD	  binding	  at	  
tetOp,	  recruiting	  other	  transcription	  factors,	  and	  leading	  to	  high	  levels	  of	  GFP.	  Because	  of	  the	  
tTA–tetO	  binding	  dynamics,	  the	  amplifier	  architecture	  allows	  for	  an	  amplified	  GFP	  output	  in	  
response	  to	  addition	  of	  ligand	  over	  the	  ribozyme	  switch-­‐only	  architecture,	  while	  retaining	  the	  
modular-­‐input	  characteristics	  of	  the	  latter.	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3.2.2 Input–output profiles of tTA expression–tetO target gene levels 
We first sought to examine the properties of GFP activation by tTA. We 
cloned two, four, or seven copies of tetO upstream the minimal CYC1 promoter 
driving GFP expression and chromosomally integrated these target constructs 
into yeast at the trp1 locus (trp::tetO2-GFP, trp::tetO4-GFP, trp::tetO7-GFP, 
respectively). We then transformed into these strains plasmids bearing tTA 
behind a GAL1 promoter (GAL1p) and titrated galactose to examine the 
relationship between tTA expression and output GFP levels allowed by our 
design architecture. To allow for tight control o tTA expression levels, the assays 
were performed in a parent strain (CSY22) in which the galactose permease 
GAL2 was knocked out to allow for linear induction of gene expression from 
GAL1p (Hawkins and Smolke, 2006). A control plasmid containing a GAL1p-GFP 
expression cassette was transformed into the trp::tetO7-GFP strain, showing that 
GAL1p induction by galactose was indeed linear and relatively weak. In contrast, 
GAL1p induction of tTA, expected to exhibit a similar expression profile as the 
GAL1p-GFP construct, led to dramatically increased GFP levels from all tetO-
containing promoters. The amplifier architecture allowed for saturating output 
GFP levels even at low induction, with EC50 values ~ 0.04% galactose, whereas 
GAL1p-GFP did not reach maximal expression in the galactose range tested 
(Figure 3.3A). The data also show that maximal expression increased with tetO 
copy number, allowing for tuning of output level, and compared favorably with 
even the highest-strength promoters commonly used in yeast (Figure 3.3C).  
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Importantly, the data indicate that GFP expression levels rose logarithmically 
with tTA induction. As discussed previously, prior work has shown that tetR 
family proteins can display cooperative binding to adjacent operator sites by 
modulating conversion of neighboring target operators from B-form DNA to the 
under-twisted form that facilitates further tetR binding (Ramos et al., 2005). We 
used GFP expression from GAL1p as a measure of tTA induction from the same 
promoter, and tetO7-GFP activation as a measure of output, to calculate a hill 
coefficient for tTA–tetO7 binding of nH,tTA ~2.47 (for comparison, the classic 
example of hemoglobin–O2 binding displays nH, Hg~2.7 in adult humans (Pittman, 
2011)), suggesting that our system is cooperative (Figure 3.3B). The 
logarithmically increasing GFP output levels from linearly increasing tTA input 
levels lend support to the hypothesis that in the regime of low tTA expression, a 
small increase in tTA could lead to a dramatic increase in target GFP levels. We 
hoped that such a situation could allow a ligand-responsive switch effecting a 
relatively modest change in tTA expression to dramatically increase GFP output 
levels. 
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Figure	  3.3	  Profiles	  of	  GFP	  target	  activation	  following	  linear	  induction	  of	  tTA	  
Linearly	  increasing	  levels	  of	  tTA	  in	  the	  amplifier	  architecture	  mediate	  robust	  and	  logarithmically	  
increasing	  levels	  of	  output	  GFP	  expression.	  (A)	  Yeast	  strains	  contain	  target	  cassettes	  composed	  
of	  tTA-­‐responsive	  promoters	  tetO-­‐2,-­‐4,	  and	  -­‐7	  	  driving	  GFP	  expression,	  and	  a	  separate	  actuator	  
cassette	  composed	  of	  galactose-­‐responsive	  GAL1p	  driving	  expression	  of	  the	  transcription	  factor	  
tTA.	  Galactose	  induction	  of	  GAL1p-­‐GFP	  (green)	  elicits	  linearly	  increasing	  and	  low-­‐level	  expression	  
of	  GFP,	  whereas	  galactose	  induction	  GAL1p-­‐tTA	  results	  in	  robust	  and	  digital	  expression	  of	  GFP	  
output	  from	  the	  various	  tetO-­‐containing	  promoters	  (purple,	  red,	  blue).	  (B)	  Hill	  plot	  of	  tTA	  
induction-­‐GFP	  output	  performance	  from	  tTA-­‐tetO7-­‐GFP	  indicate	  cooperative	  binding,	  with	  
nH~2.47.	  (C)	  Maximal	  allowed	  GFP	  expression	  from	  the	  amplifier	  designs	  compares	  favorably	  to	  
expression	  from	  the	  constitutive	  high-­‐strength	  yeast	  promoter	  TEF1p,	  and	  can	  be	  tuned	  by	  tetO	  
copy	  number.	  All	  samples	  are	  at	  2%	  galactose	  induction.	  Error	  bars	  indicate	  one	  standard	  
deviation	  from	  mean	  GFP	  levels.	  	  	  
A	  
B	   C	  
 93 
3.2.3 Ribozyme switch-mediated regulation of tTA for target expression control 
We next examined the ability of tTA regulation by small molecule-responsive 
ribozyme switches to increase the regulatory range of these RNA-based control 
elements. Several theophylline-responsive ribozyme switches previously 
developed in our laboratory (Win and Smolke, 2007) were placed in the 3’ UTR 
of the tTA gene driven by a constitutively-active TEF1 promoter (TEF1p). All 
TEF1p-tTA-riboswitch constructs led to near-saturating levels of GFP expression 
with or without theophylline, with only wild type ribozyme (RSV) abolishing 
GFP expression (Figure 3.4).  
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Figure	  3.4	  Switches	  in	  the	  amplifier	  platform	  driven	  by	  high-strength	  promoter	  TEF1	  	  
For	  ribozyme	  switches	  in	  the	  amplifier	  platform	  behind	  high-­‐strength	  promoter	  TEF1p,	  amplifier	  
platform	  fails	  to	  confer	  ligand-­‐mediated	  regulation.	  Theophylline-­‐responsive	  switches	  sdT1	  and	  
sdT8	  placed	  in	  the	  no-­‐amplifier	  GFP-­‐switch-­‐only	  platform	  (light	  green	  and	  brown)	  regulate	  GFP	  
expression	  in	  response	  to	  increased	  theophylline	  levels.	  The	  same	  switches	  behind	  TEF1p-­‐tTA	  
show	  saturating	  levels	  of	  GFP	  expression	  under	  all	  conditions	  (dark	  green,	  black).	  RSV	  is	  a	  wild	  
type	  ribozyme.	  Mean	  GFP	  levels	  are	  shown	  normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control	  
cloned	  behind	  TEF1p-­‐tTA.	  Error	  bars	  indicate	  one	  standard	  deviation	  from	  the	  mean.	  All	  
experiments	  were	  performed	  in	  a	  yeast	  strain	  containing	  trp1::tetO7-­‐GFP.	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 In the switch-only, no-amplifier architecture (containing only TEF1p-GFP-
switch) basal expression levels from these switches were all greater than 10% of 
that from a non-cleaving control ribozyme (Win and Smolke, 2007). These 
expression levels would be similar to induction of GAL1p at more than 1% 
galactose induction. At these expression levels, tTA already begins to yield 
maximal GFP expression (Figure 3.3A), explaining why any possible ligand-
induced increase in tTA protein levels would not lead to a significant increase in 
GFP expression. These results suggest that perhaps lowering overall tTA 
expression might lead to the desired high-fold modulation of target GFP levels. 
To achieve that, we tested various low-strength promoters driving a reporter 
GFP and based on the results (Figure 3.5) redesigned our tTA-switch constructs 
to be driven by STE5p, which drives expression at just 1% of that from TEF1p. 
 We cloned STE5p upstream of our various tTA-switch constructs and tested 
whether these low-expression plasmids can modulate GFP levels in response to 
theophylline. A non-cleaving ribozyme control (Ctl) resulted in GFP expression 
as high as from TEF1p-tTA-Ctl, even though tTA levels would be expected to be 
just 1% of the latter. Although we observed some theophylline-responsive 
control over GFP expression by some of our tTA-switch constructs, dynamic 
ranges were lower than in the no-amplifier GFP-switch-only context. These 
results can again be explained by our tTA input–output profile (Figure 3.3A). 
Since STE5p-tTA-Ctl already yields close to maximal GFP expression, 
riboswitches with basal expression of 10% of Ctl or higher would be expected to 
yield GFP levels at ~60% or higher in the amplifier architecture, close to the 
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values we observe. Thus, the data indicate that we need to lower tTA levels even 
further to achieve high-fold modulation of GFP expression. 
 We next obtained second-generation, low-basal level, theophylline-
responsive ribozyme switches developed in our laboratory using a high-
throughput screening method (Liang et al., 2012). These newly-developed 
switches have been shown to allow for basal levels as low as ~3% of that from 
Ctl, and dynamic ranges of up to 10 fold in response to theophylline.  To explore 
a wide array of basal states, we cloned one, two, and three copies of these 
second-generation switches (sdT8a and sdT8t) behind STE5-tTA. Additional 
ribozyme switch copies are expected to increase the likelihood of any given 
transcript being cleaved, leading to lower overall gene expression levels (Chen et 
al., 2010). In our experiments, the second-generation switches led to dramatic 
modulation of GFP expression in response to theophylline (Figure 3.7A). In 
addition, gene expression “ON” states were very high, similar to GFP levels from 
plasmids bearing non-cleaving ribozyme controls. These switches regulating tTA 
in the amplifier architecture exhibited higher-fold GFP modulation and higher 
“ON” states than the same switches directly regulating GFP (Figure 3.7B). The 
amplifier switches exhibited dynamic ranges as high as 20 fold, with maximal 
GFP expression approaching the highest levels commonly achieved in yeast. GFP 
expression in the absence of theophylline was almost indistinguishable from 
output from wild type ribozyme. In addition, GFP expression profiles were 
unimodal, with populations of cells in the presence and absence of theophylline 
showing little overlap (Figure 3.7B). 
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Figure	  3.5	  Expression	  levels	  of	  various	  promoters	  driving	  GFP	  
Various	  promoters	  upstream	  of	  GFP	  show	  different	  expression	  levels,	  shown	  here	  normalized	  to	  
expression	  from	  TEF1p-­‐GFP.	  Cells	  harboring	  no	  GFP	  gene	  are	  labeled	  as	  “none.”	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Figure	  3.6	  Switches	  in	  the	  amplifier	  platform	  driven	  by	  low-strength	  promoter	  STE5	  	  
For	  ribozyme	  switches	  in	  the	  amplifier	  platform	  behind	  low-­‐strength	  promoter	  STE5p,	  amplifier	  
platform	  confers	  modest	  ligand-­‐mediated	  regulation.	  Theophylline-­‐responsive	  switches	  sdT1	  and	  
sdT8	  placed	  in	  the	  no-­‐amplifier	  GFP-­‐switch-­‐only	  platform	  (light	  green	  and	  brown)	  regulate	  GFP	  
expression	  in	  response	  to	  increased	  theophylline	  levels,	  but	  show	  modest	  modulation	  behind	  
STE5p-­‐tTA	  (dark	  green,	  black).	  RSV	  is	  a	  wild	  type	  ribozyme.	  Mean	  GFP	  levels	  are	  shown	  
normalized	  to	  a	  non-­‐aptamer,	  non-­‐cleaving	  control	  cloned	  behind	  STE5p-­‐tTA.	  Error	  bars	  indicate	  
one	  standard	  deviation	  from	  the	  mean.	  All	  experiments	  were	  performed	  in	  a	  yeast	  strain	  
containing	  trp1::tetO7-­‐GFP.	  Expression	  from	  STE5p	  is	  ~1%	  of	  that	  from	  TEF1p.	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Figure	  3.7	  Low-basal	  level	  switches	  allow	  high	  dynamic	  ranges	  and	  "ON"	  states	  
(A)	  One,	  two,	  and	  three	  copies	  of	  theophylline-­‐responsive	  riboswitches	  sdT8a	  and	  sdT8t	  in	  the	  3’	  
UTR	  of	  tTA	  are	  able	  to	  significantly	  modulate	  GFP	  expression	  in	  response	  to	  theophylline	  
addition.	  (B)	  The	  same	  riboswitches	  in	  the	  3’	  UTR	  of	  GFP	  exhibit	  much	  lower-­‐fold	  dynamic	  range	  
than	  behind	  tTA,	  and	  also	  much	  lower	  GFP	  “ON”	  states.	  (C)	  Histograms	  show	  unimodal	  
distributions	  with	  clear	  separation	  between	  GFP	  “OFF”	  and	  “ON”	  states.	  Red,	  TEF1p-­‐GFP-­‐sdT8a,	  
Green,	  STE5p-­‐tTA-­‐sdT8a;	  solid,	  0	  mM	  theophylline,	  dotted,	  40	  mM	  theophylline.	  All	  plasmids	  are	  
expressed	  in	  a	  CSY22	  trp1::tetO7-­‐GFP	  strain.	  GFP	  values	  are	  normalized	  to	  the	  average	  from	  a	  
plasmid	  bearing	  STE5p-­‐tTA-­‐Ctl.	  Maximal	  expression	  from	  STE5p-­‐tTA-­‐Ctl	  is	  similar	  than	  from	  
TEF1p-­‐GFP-­‐Ctl.	  All	  experiments	  were	  performed	  in	  a	  yeast	  strain	  containing	  trp1::tetO7-­‐GFP.	  All	  
GFP-­‐switch	  constructs	  are	  expressed	  from	  TEF1p,	  all	  tTA-­‐switch	  constructs	  from	  STE5p.	  
Expression	  from	  STE5p	  is	  ~1%	  of	  that	  from	  TEF1p.	  
A	  
B	   C	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We then explored the regulatory dynamics of ligand-mediated gene 
expression. We titrated the theophylline inducer for switches controlling GFP 
expression directly or through the amplifier architecture. Results showed 
increased sensitivity to theophylline addition, with amplifier switches having 
IC50 values ~2–4 mM theophylline, versus >10 mM for direct GFP control 
switches (Figure 3.8). Further, for tTA-sdT8t, near-saturating GFP levels were 
observed at as low as 10 mM theophylline, whereas the same switch in the direct-
GFP architecture did not appear to reach saturation.  
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Figure	  3.8	  Regulatory	  dynamics	  of	  theophylline-induced	  riboswitch	  control	  
Ligand-­‐induced	  modulation	  of	  ribozyme	  switch	  activity	  is	  conveyed	  into	  an	  amplified	  response	  in	  
the	  amplifier	  platform.	  Switches	  sdT8a	  and	  sdT8t	  placed	  behind	  TEF1p-­‐GFP	  mediate	  higher	  GFP	  
expression	  upon	  theophylline	  induction,	  although	  maximal	  expression	  levels	  and	  dynamic	  range	  
are	  modest.	  The	  same	  switches	  in	  the	  amplifier	  context	  behind	  STE5p-­‐tTA	  mediate	  rapid	  
saturation	  of	  GFP	  output	  even	  at	  low	  theophylline	  concentration.	  Expression	  from	  STE5p	  is	  ~1%	  
of	  that	  from	  TEF1p.	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3.3 Conclusions 
We set out to develop a mechanism to amplify output gene regulation by 
ribozyme switches. Although the ribozyme switch platform exhibits a highly 
modular design, as with other classes of synthetic riboswitches, its output 
dynamic ranges have so far been modest, at most ~10 fold, and often in response 
to induction by high concentrations of input molecules (Liang et al., 2011). As 
discussed earlier in Chapter 2, this limitation may be due to the thermodynamic 
nature of their switching mechanism, making it difficult to exceed this dynamic 
range. TF-based systems, while largely exhibiting modular and high-fold 
regulation of output gene expression (Khalil et al., 2012), exhibit greater 
limitations in terms of their adaptation to different input molecules, limiting their 
widespread use for synthetic biology. 
This work resolves this problem by developing a TF-riboswitch gene 
amplifier in eukaryotes combining the modular-input characteristics of ribozyme 
switch-mediated regulation with the high-fold, modular output characteristics of 
TF-mediated gene control. The amplifier platform allows for as much as 20-fold 
regulation of output gene expression in response to input signal. EC50 values are 
more than 4 times lower than in our best-performing non-amplifier ribozyme 
switches, and maximal “ON” state gene expression approaches the highest 
expression levels commonly observed in yeast, whereas “OFF” states approach 
those from a wild type, maximally-cleaving ribozyme.   
The amplifier platform architecture allows for modularity of input stemming 
from the versatility of the riboswitch platform. The theophylline-responsive 
ribozyme switches used here can be replaced with riboswitches to novel ligands, 
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including already-developed protein-responsive ribozyme switches described in 
Chapter 2, or with more complex computational logic gates as previously 
described (Win and Smolke, 2008a). Other classes of riboswitches can also be 
potentially employed to regulate tTA levels (Babiskin and Smolke, 2011b; Liang 
et al., 2011). Further, with an ever-expanding set of RNA aptamers (Ellington, 
2004), and both rational design (Win and Smolke, 2007, 2008b) and directed 
evolution methods (Liang et al., 2012) to generate new riboswitches, there do not 
appear to be any foreseen limitations regarding choice of input molecule. While 
in this study we needed to tune promoter strength and riboswitch basal state to 
achieve high-fold modulation of output gene expression, there are myriad tools 
with which to tune expression levels (Alper et al., 2005; Babiskin and Smolke, 
2011a). The riboswitches we used also did not originally exhibit exceedingly 
large dynamic ranges, being similar to other riboswitch classes previously 
developed, indicating that the amplifier platform can likely be employed 
successfully with new inputs. Immediate future work will be aimed at 
demonstrating this explicitly.  
In addition to riboswitch-mediated, ligand-responsive regulation, TFs that 
respond to various ligands have been widely used. For example, tTA is known to 
lose its gene activation characteristics upon binding doxycycline. Similar 
transcription factors bind other inducer molecules and modulate output gene 
expression accordingly. While alone these TF-altering inducers may comprise a 
small and not generally expansible set of inputs, layered in combination with 
riboswitch-mediated control, they can provide for more sophisticated regulation 
over gene expression. 
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The amplifier platform is also designed to be modular with regards to output 
protein. tTA-responsive promoters can be placed upstream of any transgene, or 
any endogenous gene by 3’ UTR replacement (Babiskin and Smolke, 2011b). 
There is no reason to believe that the range of expression regulation of a different 
output protein would be significantly different than for our reporter GFP. 
For some applications, it may be desirable to simultaneously regulate 
different genes in response to different outputs. Previous work in yeast has 
demonstrated using modular binding domains fused to various activation 
domains to allow for orthogonal gene regulation by synthetic TFs (Khalil et al., 
2012). The limitation of this platform is lack of input modularity, as these 
synthetic TFs cannot be generally modified to respond to a new ligand. With the 
amplifier architecture, however, tTA can be modified by replacing tetR with 
these orthogonal DNA-binding domains to allow for simultaneous control over 
many genes in response to any ligand of interest to which a proper riboswitch 
can be developed. 
Another desirable characteristic of a gene control platform is to be able to set 
output gene expression at a specified level. Here we demonstrated that the 
number of tetO sites upstream our output gene can tune its expression. We show 
expression levels as high as generally observed in yeast, as well as at 
intermediate levels from lower tetO-copy promoters. It is likely that more step-
wise changes in tetO copy-number can provide even more precise control over 
output gene expression. Further, several strategies have shown that mutating 
promoter sequence can affect output strength (Alper et al., 2005), a strategy 
which we may also employ. Our platform thus seems to allow precise control 
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over “ON” state expression level, while still maintaining ability to maintain tight 
expression in the “OFF” state. 
Lastly, while we demonstrate turning gene expression “ON” in response to 
our ligand, our laboratory has developed several examples of “OFF” switches 
which we may likely employ to invert the response to ligand induction. 
Alternatively, synthetic TFs have also been developed that contain silencing 
domains (Witzgall et al., 1994), potentially allowing “ON” switches to turn gene 
expression “OFF” in response to increased ligand levels..  
While we continue to demonstrate and further develop these characteristics, 
the amplifier platform appears poised to resolve important limitations in current 
eukaryotic gene control strategies. As synthetic biology designs continue to 
evolve in sophistication, we hope that our genetic amplifier may generally be 
employed to sense varied and novel molecular inputs, to control modular 
outputs, with orthogonal, tailored, and digital regulatory responses, allowing for 
the development of powerful solutions to many pressing needs. 
3.4 Materials and Methods 
3.4.1 Plasmid and strain construction 
Standard molecular biology techniques were used for DNA manipulation and 
cloning (Sambrook, 2001). Restriction enzymes, T4 DNA ligase, and other cloning 
enzymes were purchased from New England Biolabs (Ipswich, MA). PfuUltraII 
(Agilent Technologies, Santa Clara, CA) was used for high-fidelity PCR 
amplification. LR Clonase II and BP Clonase II (Invitrogen, Carlsbad, CA) were 
used for recombination into Gateway destination plasmids (Addgene, 
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Cambridge, MA) following manufacturer’s instructions. Oligonucleotides were 
synthesized by Integrated DNA Technologies (Coralville, IA) or the Stanford 
Protein and Nucleic Acid Facility (Stanford, CA). Plasmids were transformed 
into One Shot Top 10 chemically competent E. coli (Invitrogen, Carlsbad, CA; F-
 mcrA "( mrr-hsdRMS-mcrBC) #80lacZ"M15 " lacX74 recA1 araD139 
"( araleu)7697 galU galKrpsL (StrR) endA1 nupG) by standard methods. E. coli 
were grown in LB media (BD, Franklin Lakes, NJ) with 100 $g/mL ampicillin 
(EMD Chemicals, Gibbstown, NJ) or 50 µg/mL kanamycin (EMD Chemicals, 
Gibbstown, NJ), depending on the plasmid selection gene. Plasmids were 
prepped from overnight cultures of E. coli using Econospin All-in-One Mini Spin 
Columns (Epoch Biolabs, Missouri City, TX) according to the manufacturers’ 
instructions. Sequencing was performed by Laragen Inc. (Los Angeles, CA) and 
Elim Biopharmaceuticals (Hayward, CA).  
Plasmids for tetOn-GFP target integration were based on pAG304GAL-
ccdB (Addgene, Cambridge, MA), where a stop codon was added 5’ of the 
constructs to prevent any induction from GAL1p, followed by tetOx-CYC1mp-
GFP. PCR constructs were cloned into attL1 and attR1 sites within pAG304GPD-
ccdB-EGFP (Addgene, Cambridge, MA) using BP and LR recombination 
(Invitrogen, Carlsbad, CA) following manufacturer’s instructions. Sequences of 
relevant promoters and proteins are listed in Figure 3.11. 
Plasmids for riboswitch GFP expression characterization were based on 
pCS1748, a centromeric vector encoding an mCherry gene under the control of 
a TEF1 promoter, and a yEGFP3 gene under the control of TEF1 promoter 
(Figure 2.19) described previously (Liang et al., 2012). pL192 was constructed by 
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replacing the TEF1 promoter upstream yEGFP3 by a STE5 promoter. STE5 
promoter was amplified from plasmid pJZ525, a gift from Wendell Lim 
(Department of Biochemistry and Biophysics, University of California, San 
Francisco) using primers Lcla_Ste5 (ATATatcgatATCAAGTTTCCTTTAAAGGG) 
and Rbam_Ste5* (ATATggatccCATTTAAAAGTTGTTTCCGCTGtat) and cloned 
at unique ClaI and BamHI sites upstream of yEGFP3 using appropriate 
restriction endonuclease and ligation-mediated cloning. DNA fragments 
encoding the ribozyme-based devices were synthesized as 80nt overlapping 
oligonucleotides, amplified by polymerase chain reaction, and inserted into 
either pL192 via the unique restriction sites AvrII and XhoI, which are located 3 
nucleotides downstream of the yEGFP3 stop codon. For construction of plasmids 
bearing multiple copies of a riboswitch, riboswitches were amplified by 
Rxhoxba_s8X 
(ATATctcgagtctagaTTTTTATTTTTCTTTTTGCTGTTTCGTCCTCC) and 
Lavr_s8X (ATATCCTAGGAAACAAACAAAGCTGTCACCGGA), the first copy 
cloned into the unique restriction sites AvrII and XhoI, and subsequent copies 
cloned in compatible enzyme scar method, in which further copies of 
riboswitches were digested with AvrII and XhoI, the vector by XbaI and XhoI, 
and the two ligated, resulting in a configuration of AvrII site—riboswitch—
scar—riboswitch—Xba I site—XhoI site. All switch, protein, and promoter 
sequences used are listed in Figure 3.10 and Figure 3.11. 
Individual plasmids were transformed into yeast strain CSY22, a gal2! 
mutant of W303% (MAT"; leu2-3,112; trp1-1; can1-100; ura3-1; ade2-1; his3-11,15) , 
described earlier (Hawkins and Smolke, 2006) using standard lithium-acetate 
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methods (Gietz and Woods, 2002). Yeast were grown in YPD or appropriate 
dropout media (BD, Franklin Lakes, NJ) with 2% w/v glucose. For galactose 
induction experiments, yeast were instead grown in appropriate dropout media 
with 1% w/v sucrose and the appropriate galactose concentration.  
3.3.2 Flow cytometry 
For fluorescence characterization, yeast strains were inoculated in 500 $l 
appropriate liquid drop out media in 96-well plates and grown in a Lab-Therm 
HT-X (Kühner, Basel, Switzerland) at 480 rpm, 30°C, and 80% relative humidity 
overnight with the appropriate concentration of theophylline (Sigma Aldrich, St. 
Louis, MO). The next day, samples were back-diluted to OD600 ~0.1, grown 3–6 
hours in the same conditions, and analyzed for fluorescence using a MACSQuant 
VYB (Miltenyi Biotec, Cologne, Germany). Cells were excited with a 488 nm laser 
and signal measured after passing through a 525/50 nm filter. Viable cells were 
gated by electronic volume and side scatter. Approximately 10,000 cells were 
analyzed for each culture, and the arithmetic mean fluorescence of replicate 
biological samples reported. Generally, mean GFP values were normalized by 
the mean GFP value of a non-cleaving control ribozyme. Theophylline was 
prepared as a 40 mM stock in appropriate media, and diluted when appropriate. 
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1668 NaeI (1)
1668 NgoMIV (1)
F1 ori 1781..1475
TEF1p 1999..2402
2598 BstXI (1)
ymCherry 2409..3134
2870 BseRI (1)
3135 NotI (1)
3137 SfiI (1)
CYC1t 3143..3404
3318 BsrGI (1)
3325 MluI (1)
3687 Tth111I (1)
3725 MscI (1)
3806 BbeI (1)
3806 KasI (1)
3806 NarI (1)
3806 SfoI (1)
3961 ClaI (1)
TEF1p 3965..3966
4146 PacI (1)
4192 BstEII (1)
Ste5p 3967..4466
5772 Acc65I (1)
5772 KpnI (1)
ADH1t 5532..5771
5534 AscI (1)
5526 XhoI (1)
5519 AvrII (1)
5347 SphI (1)
5333 BtrI (1)
5275 SalI (1)
5147 BsiWI (1)
5045 OliI (1)
tTA 4511..5518
4913 Eco47III (1)
4898 BstAPI (1)
4789 NruI (1)
4746 SnaBI (1)
4505 BglII (1)
4497 HindIII (1)
4485 EcoRI (1)
4467 BamHI (1)
7058 Eam1105I (1)
AmpR 7652..6993
7994 PmlI (1)
8017 SwaI (1)
CEN6_ARSH4 7982..8500
pL192
8564 bp
URA3 411..1211
616 NcoI (1)
388 SbfI (1)
532 XcmI (1)
Figure	  3.9	  Plasmid	  pL192	  for	  characterization	  of	  amplifier	  output	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Ctl sTRSV
-Ctl 
pCS1751 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTACGTGAGGTCCGT
GAGGACAGAACAGCAAAAAGAAAAATAAAAA  
RSV sTRSV pCS1750 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
GAGGACGAAACAGCAAAAAGAAAAATAAAAA 
sdT8 L2b8 pL121 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
TGTCCATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGGAGG
ACGAAACAGCAAAAAGAAAAATAAAAA 
sdT1 L2b1 pL71 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
GTCCATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGAGGAC
GAAACAGCAAAAAGAAAAATAAAAA 
sdT8a L2b8-
a1 
pCS2261 AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCTGATGAGTCCGT
TGTCCATACCAGCATCGTCTTGATGCCCTTGGCAGGGACGGGACGGAGG
ACGAAACAGCAAAAAGAAAAATAAAAA 
sdT8t L2b8-
t241 
pCS2273 AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCCGT
TGCTGATACCAGCATCGTCTTGATGCCCTTGGCAGCAGTTCAGCGGAGG
ACGAAACAGCAAAAAGAAAAATAAAAA 
Figure	  3.10	  Ribozyme	  switch	  device	  sequences	  used	  in	  experiments	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KZ  TAAAAAAAATG 
STE5p pL192 ATCAAGTTTCCTTTAAAGGGATATATAACAGATTCTAAAACTGACAG
AAATATTTCGAGTGAAGAAGAAGCGTTAAATATTGGATCTTTCCGCA
GTTCTACTCTGATACATTTTTGAAGTAGGAGAGTCATTTAGAAGGCG
TATTGCTCAATAGTAGAAAGCAGGCCTGTGCACATGAATTAATTAAA
AAATATAAAGGTAGTGATTAGACGACACATGTCCATAGGTAACCTGT
CATAATTTTGAACAATTTCCCTTCTTTTCTTTTTTTTTTTTGGGTGC
GGCGATATGTAGCTTGTTAATTTACACATCATGTACTTTTCTGCATC
AAAATATGAAAGGCGATAGTAGCTAAAGAAAATACCGAGAATTTCCT
CGAAAAGTTGACGACAAAAGAAAGGCATAAAAAAGTAATTTGAAAAT
ATTTTAAAACTGTTTTAACCCATCTAGCATCCGCGCTAAAAAAGGAA
GATACAGGATACAGCGGAAACAACTTTTAA  
TEF1p pCS1748 ATAGCTTCAAAATGTTTCTACTCCTTTTTTACTCTTCCAGATTTTCT
CGGACTCCGCGCATCGCCGTACCACTTCAAAACACCCAAGCACAGCA
TACTAAATTTCCCCTCTTTCTTCCTCTAGGGTGTCGTTAATTACCCG
TACTAAAGGTTTGGAAAAGAAAAAAGAGACCGCCTCGTTTCTTTTTC
TTCGTCGAAAAAGGCAATAAAAATTTTTATCACGTTTCTTTTTCTTG
AAAATTTTTTTTTTTGATTTTTTTCTCTTTCGATGACCTCCCATTGA
TATTTAAGTTAATAAACGGTCTTCAATTTCTCAAGTTTCAGTTTCAT
TTTTCTTGTTCTATTACAACTTTTTTTACTTCTTGCTCATTAGAAAG
AAAGCATAGCAATCTAATCTAAGTTTTG 
ADH1p pL203 TAAAACAAGAAGAGGGTTGACTACATCACGATGAGGGGGATCGAAGA
AATGATGGTAAATGAAATAGGAAATCAAGGAGCATGAAGGCAAAAGA
CAAATATAAGGGTCGAACGAAAAATAAAGTGAAAAGTGTTGATATGA
TGTATTTGGCTTTGCGGCGCCGAAAAAACGAGTTTACGCAATTGCAC
AATCATGCTGACTCTGTGGCGGACCCGCGCTCTTGCCGGCCCGGCGA
TAACGCTGGGCGTGAGGCTGTGCCCGGCGGAGTTTTTTGCGCCTGCA
TTTTCCAAGGTTTACCCTGCGCTAAGGGGCGAGATTGGAGAAGCAAT
AAGAATGCCGGTTGGGGTTGCGATGATGACGACCACGACAACTGGTG
TCATTATTTAAGTTGCCGAAAGAACCTGAGTGCATTTGCAACATGAG
TATACTAGAAGAATGAGCCAAGACTTGCGAGACGCGAGTTTGCCGGT
GGTGCGAACAATAGAGCGACCATGACCTTGAAGGTGAGACGCGCATA
ACCGCTAGAGTACTTTGAAGAGGAAACAGCAATAGGGTTGCTACCAG
TATAAATAGACAGGTACATACAACACTGGAAATGGTTGTCTGTTTGA
GTACGCTTTCAATTCATTTGGGTGTGCACTTTATTATGTTACAATAT
GGAAGGGAACTTTACACTTCTCCTATGCACATATATTAATTAAAGTC
CAATGCTAGTAGAGAAGGGGGGTAACACCCCTCCGCGCTCTTTTCCG
ATTTTTTTCTAAACCGTGGAATATTTCGGATATCCTTTTGTTGTTTC
CGGGTGTACAATATGGACTTCCTCTTTTCTGGCAACCAAACCCATAC
ATCGGGATTCCTATAATACCTTCGTTGGTCTCCCTAACATGTAGGTG
GCGGAGGGGAGATATACAATAGAACAGATACCAGACAAGACATAATG
GGCTAAACAAGACTACACCAATTACACTGCCTCATTGATGGTGGTAC
ATAACGAACTAATACTGTAGCCCTAGACTTGATAGCCATCATCATAT
CGAAGTTTCACTACCCTTTTTCCATTTGCCATCTATTGAAGTAATAA
TAGGCGCATGCAACTTCTTTTCTTTTTTTTTCTTTTCTCTCTCCCCC
GTTGTTGTCTCACCATATCCGCAATGACAAAAAAATGATGGAAGACA
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CTAAAGGAAAAAATTAACGACAAAGACAGCACCAACAGATGTCGTTG
TTCCAGAGCTGATGAGGGGTATCTCGAAGCACACGAAACTTTTTCCT
TCCTTCATTCACGCACACTACTCTCTAATGAGCAACGGTATACGGCC
TTCCTTCCAGTTACTTGAATTTGAAATAAAAAAAAGTTTGCTGTCTT
GCTATCAAGTATAAATAGACCTGCAATTATTAATCTTTTGTTTCCTC
GTCATTGTTCTCGTTCCCTTTCTTCCTTGTTTCTTTTTCTGCACAAT
ATTTCAAGCTATACCAAGCATACAATCAACTATCTCATATACA  
CYC1p pL108 GAGCAGATCCGCCAGGCGTGTATATATAGCGTGGATGGCCAGGCAAC
TTTAGTGCTGACACATACAGGCATATATATATGTGTGCGACGACACA
TGATCATATGGCATGCATGTGCTCTGTATGTATATAAAACTCTTGTT
TTCTTCTTTTCTCTAAATATTCTTTCCTTATACATTAGGACCTTTGC
AGCATAAATTACTATACTTCTATAGACCCACAAACACAAATACCCCC
CCTAAATTAATA  
CYC1mp pL74 TATGGCATGCATGTGCTCTGTATGTATATAAAACTCTTGTTTTCTTC
TTTTCTCTAAATATTCTTTCCTTATACATTAGGTCCTTTGTAGCATA
AATTACTATACTTCTATAGACACGCAAACACAAATACACACACTAAA
TTACCG 
tetO7-
CYC1m 
pL74 CTTATTGACCACACCTCTACCGGCAGATCCGCTAGGGATAACAGGGT
AATATAGATCAATTCCTCGA 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
TCGAGCTCGGTACCC 
TATGGCATGCATGTGCTCTGTATGTATATAAAACTCTTGTTTTCTTC
TTTTCTCTAAATATTCTTTCCTTATACATTAGGTCCTTTGTAGCATA
AATTACTATACTTCTATAGACACGCAAACACAAATACACACACTAAA
TTACCG 
GATCAATTCG 
tetO pL74 TCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAG 
tTA pL192 ATGTCTAGATTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCT
GCTTAATGAGGTCGGAATCGAAGGTTTAACAACCCGTAAACTCGCCC
AGAAGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAAT
AAGCGGGCTTTGCTCGACGCCTTAGCCATTGAGATGTTAGATAGGCA
CCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTT
TACGTAATAACGCTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGC
GATGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTA
TGAAACTCTCGAAAATCAATTAGCCTTTTTATGCCAACAAGGTTTTT
CACTAGAGAATGCATTATATGCACTCAGCGCTGTGGGGCATTTTACT
TTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAGA
AAGGGAAACACCTACTACTGATAGTATGCCGCCATTATTACGACAAG
CTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTC
GGCCTTGAATTGATCATATGCGGATTAGAAAAACAACTTAAATGTGA
AAGTGGGTCCGCGTACAGCCGCGCGCGTACGAAAAACAATTACGGGT
CTACCATCGAGGGCCTGCTCGATCTCCCGGACGACGACGCCCCCGAA
GAGGCGGGGCTGGCGGCTCCGCGCCTGTCCTTTCTCCCCGCGGGACA
CACGCGCAGACTGTCGACGGCCCCCCCGACCGATGTCAGCCTGGGGG
ACGAGCTCCACTTAGACGGCGAGGACGTGGCGATGGCGCATGCCGAC
GCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGGGATTCCCC
GGGTCCGGGATTTACCCCCCACGACTCCGCCCCCTACGGCGCTCTGG
ATATGGCCGACTTCGAGTTTGAGCAGATGTTTACCGATGCCCTTGGA
ATTGACGAGTACGGTGGGTAG 
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yEGFP3 pCS321 ATGTCTAAAGGTGAAGAATTATTCACTGGTGTTGTCCCAATTTTGGT
TGAATTAGATGGTGATGTTAATGGTCACAAATTTTCTGTCTCCGGTG
AAGGTGAAGGTGATGCTACTTACGGTAAATTGACCTTAAAATTTATT
TGTACTACTGGTAAATTGCCAGTTCCATGGCCAACCTTAGTCACTAC
TTTCGGTTATGGTGTTCAATGTTTTGCGAGATACCCAGATCATATGA
AACAACATGACTTTTTCAAGTCTGCCATGCCAGAAGGTTATGTTCAA
GAAAGAACTATTTTTTTCAAAGATGACGGTAACTACAAGACCAGAGC
TGAAGTCAAGTTTGAAGGTGATACCTTAGTTAATAGAATCGAATTAA
AAGGTATTGATTTTAAAGAAGATGGTAACATTTTAGGTCACAAATTG
GAATACAACTATAACTCTCACAATGTTTACATCATGGCTGACAAACA
AAAGAATGGTATCAAAGTTAACTTCAAAATTAGACACAACATTGAAG
ATGGTTCTGTTCAATTAGCTGACCATTATCAACAAAATACTCCAATT
GGTGATGGTCCAGTCTTGTTACCAGACAACCATTACTTATCCACTCA
ATCTGCCTTATCCAAAGATCCAAACGAAAAGAGAGACCACATGGTCT
TGTTAGAATTTGTTACTGCTGCTGGTATTACCCATGGTATGGATGAA
TTGTACAAATAA 
Figure	  3.11	  Coding	  and	  promoter	  sequences	  used	  for	  plasmid	  construction	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Chapter 4 
Conclusions and future directions 
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Natural biological diversity promises spectacular possibilities for synthetic 
biology. Advances in the understanding of gene function and biological system 
design have allowed for the development of novel life with characteristics that 
are already beginning to address important societal needs. By reengineering 
metabolic pathways, researchers have created organisms that produce a wide 
array of important compounds, including medicines (Ro et al., 2006; Hawkins 
and Smolke, 2008) and biofuels (Atsumi et al., 2008; Dellomonaco et al., 2011). 
And by engineering human cells, other research has allowed for the 
reprogramming of cells to many desired tissues, for tailored immune cell-
mediated targeting of cancers, and for rectification of aberrant gene expression 
(Yu et al., 2007; Santiago et al., 2008; Chen et al., 2010). 
For many potential applications, however, existing gene-regulatory schemes 
hinder the development of more sophisticated control over gene expression. In 
eukaryotic cells, in particular, few engineered platforms allow for the 
customizable reprogramming of cells. Such platforms are generally either not 
modular, not applicable in organisms of interest, or not able to meet 
requirements needed for robust and reliable modulation of target gene 
expression. This work expanded our current capabilities in two directions: by 
expanding input modularity to be able to sense protein inputs, and by 
amplifying the range of output gene modulation. 
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As a result, it may be possible to build on these developments and create 
better-performing applications. For example, our ability to use the ribozyme 
switch platform to sense protein inputs may allow us to employ this platform for 
safer cellular reprogramming in human cells. This platform, containing no 
component heterologous proteins, may be free of the immunogenicity concerns 
that generally prevent the use of TF-based gene control in humans. With our 
now-expanded ability to detect protein inputs, we extend our ability to detect 
cellular states. Many characteristics of proteins make them excellent candidates 
as input molecules. For instance, high intracellular concentrations—average of 
~1$M (Ghaemmaghami et al., 2003; Lu et al., 2007)—and wide availability of 
RNA aptamers that bind cognate proteins with often nM affinity appear 
promising parameters for design of gene control that responds to relevant 
changes of an input molecule.  Additionally, current biochemical understanding 
often provides ample knowledge about what changes in protein expression are 
associated with aberrant cell function. It may be possible to use this information 
to design ribozyme switches that can detect these protein markers, and effect 
necessary cellular reprogramming by modulating expression of target genes.  
Perhaps one shortcoming of this platform is a modest dynamic range, which 
may be a problem for some applications. We discussed earlier that this might be 
an inherent problem of the designs. Thermodynamic switches, which our data 
seem to insinuate our strand-displacements switches are examples of, may 
sacrifice dynamic range for accessibility of the different regulatory folds.  The 
modest dynamic ranges may thus be a characteristic constraint of the platform.  
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Our amplifier platform largely addresses this shortcoming, as we move closer 
to the type of regulation observed in natural systems, and learn important 
lessons about possible reasons why nature evolved such architectures. Although 
there are many examples of naturally occurring riboswitches (Serganoc and 
Nudler, 2013), generally gene control is more often mediated by proteins, and 
largely by transcription factors. This may stem from the greater diversity of 
structure, and probably function, allowed from greater number of amino-acid 
building blocks compared to nucleic acid building blocks. Today, with the 
guidance of evolution, the species that more often mediate ligand-dependent 
control over gene expression are TFs. It may be that these species are the best 
options for mediating gene control. Earlier, we discussed characteristics of TF 
structure, including an often-repeated architecture of multimeric proteins 
binding repetitive DNA sites, sometimes cooperatively. Such was indeed the case 
for our amplifier platform, which allowed for high-fold regulation of gene 
expression levels. It may thus be that in the distant future, when we may be able 
to engineer proteins with customizable input domains, that we will be using 
synthetic custom TFs to regulate gene expression.  
However, one general limitation of TF systems is immunogenicity associated 
with expression of heterologous proteins in vertebrates, limiting their use for 
many important applications. Perhaps in the distant future, such an 
immunogenic response may be prevented, either by somehow modulating the 
immune system, or by constructing synthetic TFs in a way that doesn’t cause an 
immune response. In the near future, however, this limitation will continue to 
limit the use of TF-based strategies in humans. The amplifier platform, perhaps, 
  
115 
may be an exception. While general expression of a heterologous protein may be 
immunogenic, it may be that in our amplifier, the low-level expression of the TF 
needed to elicit high-level expression of an output gene may not cause a 
problem. Many TF-based systems function by constitutive high-expression of a 
TF, where ligand binding alters not the expression level of the TF, but its 
conformation, modulating output. Our amplifier system, by contrast, is basally 
“OFF.” We only need very low-level expression of the transgenic tTA to elicit 
output protein expression. In yeast, basal expression of tTA was set to levels 
allowed by STE5 promoter, and further abrogated by our switches. For sdT8a, for 
example, basal expression would be expected to be at 3% of 1% of that allowed 
by, say, TEF1 promoter, a commonly used constitutive promoter—a very low 
value. And “ON” state expression was seen at very low induction of tTA by a 
GAL1 promoter in our cell strain, which again we chose because it allowed for 
low-level, titratable galactose induction. Potentially, the fact that we need very 
low levels of the synthetic TF inducer, if also a characteristic of a working human 
cell-version of the amplifier platform, may lower concerns for immunogenicity.   
Even in applications in lower eukaryotes, such as for the construction of 
synthetic metabolic pathways in yeast, there are still limitations for widespread 
use of TF-based systems. For example, it remains exceedingly difficult to predict 
what protein sequence might fold into a given input domain. Indeed, it is 
difficult in general to generate a novel input domain, whether via rational design 
or directed evolution strategies. Thus, it may prove difficult for some time to 
develop TFs that respond to novel inputs. Our amplifier then remains a very 
good option. It’s modular. And it has near-digital output. It may even help with 
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the development of new protein function. Even with many methods to generate 
novel biological functionality, whether by directed evolution of proteins, 
genome-wide genetic manipulation, or other technologies, measuring the effect 
of such manipulation on a given performance parameter may be difficult for 
many applications. Recently, a strategy was demonstrated for using 
theophylline-binding ribozyme switches to evolve enzymes with increased 
theophylline-producing properties (Michener and Smolke, 2012). Because RNA 
aptamers, and ribozyme switches, may perhaps generally be employed to detect 
a metabolite of interest, this strategy may be widely helpful. One hindrance, 
however, was the low dynamic range of the switch employed. Low-fold changes 
in reporter expression may be difficult to distinguish from signal noise. The 
amplifier perhaps might improve signal to noise ratios, simplifying this 
evolutionary method. 
 The work described here constitutes what may be important improvements 
over current synthetic gene control schemes in eukaryotes, combining greater 
modularity with near-digital control over output protein expression. In the near 
future, it will be important to further demonstrate the modularity and versatility 
of these platforms to allow for,  perhaps, when combined with other tools such 
as complex genetic circuits, gene evolution strategies, and improved 
understanding of biological design principles, greater capabilities for synthetic 
biology to address many pressing societal needs.  
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